## **Ensuring no one faces kidney disease alone**
**Kidney Care UK Trustees’ report and financial statements for the year ended 31 December 2024**
The British Kidney Patient Association operating as Kidney Care UK (a company limited by guarantee) Registered number: 1228114 Charity number: 270288 Charity number (Scotland): SC048198
## **Contents**
## **About Kidney Care UK**
- **4** Foreword from our CEO Paul Bristow and Chair of Trustees, Dr Graham Lipkin
- **8** Kidney Care UK’s vision and mission
- **10** Trustees statement
- **12** Being there for the kidney community for 50 years
- **14** 2024 at a glance
- **16** How our services supported patients and their families in 2024
- **17** How we spent our funds in 2024
## **Patient Support Services**
- **18** Information, advice and guidance through our Patient Support & Advocacy Service
- **20** Our Specialist Money & Energy Advice Service guides patients from financial crisis to stability **22** Establishing a new vital Peer Support service
- **24** Emotional support thorough our dedicated free Counselling service
- **26** Patient grants to help people with kidney disease live life to the full
- **28** The chance to have a break, through the Kidney Care UK Dialysis Freedom service
- **30** Launch of our free dedicated Support Line, providing reassurance and trusted advice
- **32** Supporting young adults through our online community and residential weekend
- **34** Patient information: providing patients with accessible, trustworthy and
- empowering information
- **36** Kidney Kitchen: ensuring delicious food is back on the table when you have kidney disease
- **38** Giving people with kidney disease access to the best online information, tools and support
- **40** Educating and informing people through our regular Kidney Matters magazine
## **Improving life for kidney patients**
- **42** Investing in improvements to kidney care through our Hospital Grants programme
- **43** Investing in a major national change programme through our Advanced Kidney Care Clinics project
- **44** The Kidney Patient Reported Experience Measure (PREM)
- **46** Empowering patients to take more control and play a shared role in their care
- **47** Empowering patients to take more control and fit their healthcare around their lives through the national DAYLife project
**----- Start of picture text -----**
2
**----- End of picture text -----**
## **Campaigning and patient involvement**
- **48** Policy and campaigns: ensuring patients’ views are effectively represented and campaigning for better care
- **50** Our Bloody Amazing Kidneys campaign
- **52** Our patient advisory group (PAG)
- **53** Raising standards and increasing patient involvement
## **Charity management and financial statements**
- **54** Managing our Charity as effectively and efficiently as possible
- **56** Fundraising
- **62** Looking ahead to 2025
- **64** Our financial statements: financial review of the year
- **73** Reference and administrative details of the Charity, its Trustees and advisors
- **75** Statement of Trustees’ responsibilities
- **77** Auditors’ report
- **83** Statement of financial activities (incorporating income and expenditure account)
- **84** Balance sheet
- **86** Statement of cashflows
- **87** Notes to the financial statements
**----- Start of picture text -----**
“
**----- End of picture text -----**
Sue Fisher is a kidney patient on dialysis and was struggling with her bills including water. She was in debt with her water company, but after a visit from Kidney Care UK and Wessex and Bristol Water she was helped to get things back on track.
Living with kidney disease has had an impact on so many areas of my life, but especially financially. They asked me how much I could afford to pay each month to reduce the debt, and we settled on an amount that does not overstretch me. On the whole, they were amazing.
**Sue Fisher, kidney patient 3**
## **Foreword from our**
One in 10 people in the UK have chronic kidney disease (CKD), a lifelong condition with no cure. As we enter our 50th year as the UK’s leading kidney patient support charity, Kidney Care UK has increased our direct support services to patients, engaged with more professionals to improve NHS service delivery and acted as a stable constant presence, offering trusted advice, information and lobbying at a time of turmoil in the NHS. In 2024, highlights included:
- £5.6 million spent supporting patients
- More than 8,000 patients and families supported
- Nearly £2m in welfare and benefits income secured for patients
- More than 800,000 patient information resources accessed
2024 was another year of transformation and growth for Kidney Care UK, as we continued to reach and support even more patients and their families. We are determined that everyone affected by kidney disease is aware of the Charity and can turn to us for the advice, guidance and support they need. As a result, and thanks to the generosity of our supporters, we have expanded our services to meet patients’ needs in these challenging times.
To enable this growth, we increased our expenditure on charitable activity by 26%, from £4.5m in 2023 to £5.7m in 2024, all made possible by an increase in fundraised income from £3m in 2023 to £4.1m in 2024, along with our ongoing commitment to responsibly draw down from our capital investments to fund greater patient support.
Life continues to be challenging for kidney patients, and the need for our support grows as we ensure we are there for all the patients and families who need us. We were delighted to embark on a significant expansion of our welfare and wellbeing service, which launched in Wales in 2023 and provides in-depth, personal support for everyone preparing for or receiving treatment for kidney failure.
We were able to more than double the size of our Patient Support & Advocacy team on the ground, increasing our presence in healthcare settings and extending the service to support patients across Scotland, and the north west, north east, south east, and south west of England, providing support to thousands more patients across more than half the UK.
**----- Start of picture text -----**
4
**----- End of picture text -----**
## **and Chair of Trustees,**
We also launched a free patient support line, ensuring that patients who reach out to us are able to talk immediately to someone who “gets” kidney disease, as well as working with the London Kidney Network to launch a new regional model of peer support that combines the support of the Charity with healthcare champions in every London hospital.
Our growth wasn’t just about greater personal oneto-one support, as we developed our information and communication channels to ensure people are able to access the information they want in a format that suits them. We launched a new website, resulting in an increase in website visitors of over 40%, to just shy of 1.5 million. Our patient information partnership with the UK Kidney Association also expanded as we sought to ensure high quality, trusted information is available to all patients wherever they receive their care, with over 300,000 leaflets distributed.
Our partnership approach of working with healthcare professionals and organisations to improve kidney services saw a significant development, with the launch of a national quality improvement project — Transform AKC — with the UK Kidney Association (UKKA) and NHS trusts across the UK, to improve the quality of advanced kidney care clinics.
**----- Start of picture text -----**
5
**----- End of picture text -----**
The project is designed to improve NHS service delivery at this critical focal point for those with advanced kidney disease, and support patients at this pivotal part of their kidney journey where decisions on pre-dialysis transplantation and access to home dialysis, as well as conservative care where appropriate, are taken following shared decision making.
We continued this strategic theme of reaching people early with the launch of a new national campaign to promote early diagnosis and treatment of chronic kidney disease: #BloodyAmazingKidneys. The campaign both raises awareness and provides patients, via a digital kidney health checker, with the tools to see if they are at increased risk of CKD and to help them feel confident in raising their concerns with their GP. By the end of the year almost 120,000 people had completed a kidney health check.
To support these developments, we have continued to work to ensure our organisation infrastructure is robust enough to accommodate such growth and expansion, that our operation remains efficient to ensure that every pound we are donated is well spent and that our values and staff wellbeing are prioritised to ensure we remain the patient-focused, caring organisation we have always been.
2025 sees Kidney Care UK reach the milestone of our 50th anniversary, and we start the year a bigger, better charity. We may have changed in size as an organisation, but at our heart we are the same Charity started in 1975 by a mother, Elizabeth Ward, who was determined to fight for her son’s care and quality of life. We have achieved a great deal, but we know that there is more to be done to help kidney patients and their families live well with kidney disease. The future remains uncertain and challenging for patients, but with the continued support and generosity of our supporters and staff we aim to celebrate our 50 years by helping more patients than ever before and ensuring no one has to face kidney disease alone.
**Paul Bristow, Chief Executive**
**Dr Graham Lipkin MB ChB, BSc, MD, FRCP (UK) , Chair of Trustees**
**----- Start of picture text -----**
6
**----- End of picture text -----**
**“ 2025 sees Kidney Care UK reach the milestone of our 50th anniversary, and we start the year a bigger, better charity. We may have changed in size as an organisation, but at our heart we are the same Charity started in 1975.**
**----- Start of picture text -----**
“
**----- End of picture text -----**
## **Our vision: all kidney patients can live their life to the full**
**Our mission: to improve the quality of life for everyone affected by kidney disease**
Kidney Care UK is the UK’s leading kidney patient support charity, working to improve the quality of life for everyone affected by kidney disease and raising awareness of kidney disease amongst the wider public. We provide practical, financial and emotional support to patients and their families, work in partnership with health professionals and statutory bodies to improve the access and quality of health and care services. We also represent the patient voice in campaigning for change in policy and practice.
A diagnosis of CKD can be devastating, placing a considerable toll on patients and their loved ones. The condition affects every aspect of an individual’s life including physical health, emotional wellbeing, finances and relationships, as well as employment and lifestyle. We work every day to change lives for patients, whatever their age, wherever they are in the UK and at whatever stage of the disease they might be. With our help no one should face kidney disease alone.
**8**
Irrr
i)
657
T/
## **Trustees statement**
The Trustees (who are also directors of the Charity for the purposes of Company Law) present their annual report, which incorporates the directors’ report, the strategic report, and the financial statements of The British Kidney Patient Association (BKPA), operating as Kidney Care UK, for the year ended 31 December 2024.
The annual report and financial statements comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice (SORP 2019) applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).
Since the charitable company qualifies as medium under section 382, the Strategic Report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors’ Report) Regulations 2013 is included. The Strategic Report comprises Our impact in 2024, Our Financial Review and Our Principal Risks and Controls. The legal status and governance structure is explained in the “Structure, governance and management” section of this report on pages 68 to 70. The Trustees confirm that they have complied with the duty in Section 17 of the Charities Act 2011 to have due regard to public benefit guidance published by the Charity Commission in determining the activities undertaken by the charity.
## **Our charitable objects as set out in our articles of association are:**
**1.**
To educate and inform the public regarding all forms of kidney and associated disorders.
**2.**
To promote the welfare of persons suffering from kidney and renal diseases or associated disorders (“Kidney Patients”) including providing them with financial assistance.
To make grants to hospitals for new buildings and other construction works for kidney units, for facilities for kidney transplantation, dialysis and their renal treatment and to meet cost of employing personnel to provide renal services.
To fund research for the benefit of kidney patients.
**----- Start of picture text -----**
10
**----- End of picture text -----**
**3.**
**4.**
**Kidney Care UK 5 year strategy (2021-2025) Strategic objectives:**
To reach and engage more individuals and families living with chronic kidney disease (CKD).
**To work in partnership to improve the way kidney patients are cared for across the UK.**
**To ensure patient views are effectively represented and campaign for better patient care.**
**To manage our Charity as effectively and efficiently as possible.**
**To inspire more people to support our work and develop a mature fundraising portfolio.**
**----- Start of picture text -----**
11
**----- End of picture text -----**
## **Being there for the kidney**
BKPA founder Elizabeth Ward following the Granada TV Appeal in 1978, which achieved a Guinness World Record.
HRH Diana, Princess of Wales, and Elizabeth Ward opening the paediatric renal unit at Yorkhill Hospital, Glasgow in 1983.
**----- Start of picture text -----**
12
**----- End of picture text -----**
Elizabeth Ward with Tony Blair, Prime Elizabeth Ward with former Kidney Care UK Photo caption Minister 1997-2007. CEO Paddy Tabor in 2017.
2024 at a glance
. £5.6m
Morethan
Spent on
8.000
charitable
activities
kidney patients and
families helped
Printed patient
information
resources supplied
£3.46m
811k
invested in
staff and care
services
for patients
individuals received
helpwith
1.832 .:...,:
assistance
£608K
given in grants to
help cope with
unexpected bills
Over
£1.9m
4,800
in benefits income
securedforfamilies
facing hardship
4.201
patients supported with
counselling. debt
advice and advocacy
fundraisers and
supporters
making it all possible
14
Almost
120.000
There were
people completed our
3.750
online Kidney
Health Checker
support line users
791 pieces of media
coverage with
a reach of
Wewona
partnership
award
forourcollaboration
with Anglian Water
atthe Collaboration
NetworkAwards
35.4m
people
12.966
people in ouronline community,
an increase of 8Y
The Diary of a Kidney Warrior Podcastwon
the GXAward for Best Podcast and saw a
410A increase in downloads
Our supporters raised over
£3.3m
Oursocial media
audience
grew by
to support people living
with kidney disease,
an increase of 43Y
21/
15
## **How our services supported patients**
Kidney disease affects more than 7 million people in the UK, equivalent to 1 in every 10 people, with around half of those living with the more advanced stages of chronic kidney disease (CKD). Kidney disease impacts all aspects of life, with individuals living with the disease more likely to be economically disadvantaged, and more likely to experience low mood and depression.
**----- Start of picture text -----**
16
**----- End of picture text -----**
## **How we spent our funds**
The demand for our support has never been greater, which is why we want to reach and engage with as many people as possible. We help them understand what a diagnosis of kidney disease means to them and their loved ones, as well as providing the emotional, financial and practical support they need to be able to live with a condition that has no cure.
**----- Start of picture text -----**
17
**----- End of picture text -----**
## **Patient Support Services**
## **Information, advice and guidance through our Patient Support & Advocacy service**
2024 was a transformational year for the Patient Support & Advocacy service, thanks to funding secured through our Gas Distribution Network Partners (Cadent, SGN, Wales and West Utilities and Northern Gas Networks) for our Safe and Warm programme. The expansion of the service builds on the experience of working with the Welsh Kidney Network to embed welfare and wellbeing support for dialysis patients across Wales, made possible with the generous support of Wales & West Utilities, which since its inception in 2023, has successfully helped more than 1,700 patients across Wales.
We were delighted to extend this model of support to Scotland and several regions in England covering a patient population of nearly 9,000 dialysis patients. To deliver welfare and wellbeing support we recruited a brilliant group of new professionals, bringing our frontline team to 28, supported by a new regional management team of six.
Across the UK, the service retains its clear focus on ensuring that patients have access to help at every stage of their diagnosis and treatment, providing vital financial, practical and emotional support. Our team have established strong working relationships with treatment centres nationwide, connecting with patients regularly in kidney clinics.
Our expanded service has allowed us to take our support directly to the patient community, ensuring they not only receive the help they need but also are aware of the further support offered by Kidney Care UK should it be needed in the future. Whether answering a simple question or working alongside patients over time to address complex needs, the Patient Support & Advocacy service has delivered critical, life changing support to more people in 2024, and will continue to do so in the years ahead.
**----- Start of picture text -----**
18
**----- End of picture text -----**
After his kidney disease diagnosis in 2022, Lee felt like he had no support and at one point was made homeless. Lee contacted the Patient Support & Advocacy service, and his Patient Support Officer referred him to extra support with debt after he had to stop work, helped him secure food parcel vouchers from his local food bank, and supported him to secure safe accommodation.
## **“**
I was that low psychologically that if Kidney Care UK hadn’t been there, I would have stopped taking my medication and I would have opted out of dialysis. If you are having a bad day, ring up Kidney Care UK and they will help you. You are not alone. Thank you to everyone at the Charity.
**Lee In 2024 there were new patient** 4,546 **referrals to our service, an increase of 37% compared to 2023**
**----- Start of picture text -----**
19
**----- End of picture text -----**
## **Patient Support Services**
## **Our Specialist Money & Energy Advice service guides patients from financial crisis to stability**
This year, building on the specialist Money & Energy Advice service introduced in 2023 at the peak of the cost-of-living crisis, we have responded to the increasing demand for support to navigate welfare benefits, income maximisation and energy efficiency guidance with significant growth in the service. The team works remotely with patients, guiding them from financial crisis to stability, by providing expert advice. The Money & Energy Advice service helps patients access all the welfare benefits they are entitled to.
With ongoing support from British Gas Energy Trust and new advisers funded by the Gas Distribution Networks , we’ve increased our reach, delivering vital financial support to more vulnerable individuals across the UK. This expansion has enabled the Charity to develop a comprehensive model of financial support, shaped around individual needs of patients.
Alongside our free online self-help tools (Benefits Calculator and Personal Independence Payment Helper) and our Patient Support & Advocacy Officers, the Money & Energy Advice Service plays a crucial role in ensuring patients are connected to the right support at the right time. Our advisers empower individuals to secure the support they are entitled to, giving them greater financial stability. Once that foundation is in place, we offer further assistance, helping patients review utility tariffs and access energy saving guidance to reduce everyday living costs.
At a time when the cost of living impacts the patient community more than most, this support has never been more critical. Thanks to our dedicated service funding, we have also been able to provide practical assistance, distributing electric blankets to keep patients warm during the winter months and energy saving light bulbs to help reduce fuel costs, ensuring those in need receive direct, tangible help.
£1,890,431 **financial gains realised across all financial support mechanisms**
**----- Start of picture text -----**
20
**----- End of picture text -----**
**----- Start of picture text -----**
“
**----- End of picture text -----**
Andrew Harris was diagnosed with kidney failure in 2021 and had to give up his business. He lived off his savings until they ran out. With money worries mounting, he contacted Kidney Care UK.
Kate, his Money & Energy Adviser, discovered he was not on the Priority Services Register (PSR) for any of his utility suppliers. She also identified benefit payments Andrew was entitled to, the first being Personal Independence Payment (PIP). Kate helped Andrew complete the form and talked him through what to expect when he received his assessment date.
Andrew’s PIP application was successful and he was awarded the PIP standard daily living component and enhanced mobility, with a backdated payment. Andrew also applied for Universal Credit and was awarded the standard allowance and ‘limited capacity for work-related activity’ allowance. He was able to claim Council Tax Support, which has seen his bill reduce substantially. In total, with Kate’s help, Andrew will be better off by £19,100 a year.
Applying for PIP was particularly stressful and I couldn’t deal with it on my own. I’ve always been someone who is able to sort things out but felt quite overwhelmed by this. Kate has been brilliant and is always there to help me. She’s taken a huge weight off my shoulders, so now I can focus on dialysis instead of worrying about money. **Andrew Harris**
**----- Start of picture text -----**
21
**----- End of picture text -----**
## **Patient Support Services**
## **Establishing a new vital Peer Support service**
The opportunity to speak with someone else who has been through what you are facing offers information, comfort and hope. When patients are diagnosed or embarking on a new treatment, speaking to someone who shares tips about what they take from home to make their dialysis more comfortable, for example, or things they do to protect their fistula, really prepares patients for meeting the challenges with a positive approach.
The successful launch of our Peer Support service this year has created new opportunities for people to seek information and support. Responding to demand from patients, carers and kidney health professionals, the pilot service, delivered in partnership with the London Kidney Network, has been well received across the London area and plans are being developed to extend it to the rest of the country. The Peer Support service offers people living with kidney disease the chance to be supported by someone who has lived experience of kidney disease and who knows what they are going through. We also support family members, carers and donors.
The Kidney Care UK Peer Support service provides comprehensive training for volunteers, following a UK Kidney Association-endorsed programme, managing the onboarding process to ensure safeguarding and support is robust for both volunteers and service users. All matches are made personally and followup with peer support recipients ensures any further questions or support are addressed to enable them to make choices about their treatment and lifestyle based on sound knowledge and improved confidence.
**In 2024 there were** 162 referrals for peer support **received both directly and from renal care staff in the first six months of the service**
**----- Start of picture text -----**
22
**----- End of picture text -----**
## **“**
**Martin** [ **m** y peer supporter] was truly an excellent listener and we got on very well. He asked me to tell him a bit about me and my situation and we went from there, he empathised with me. He was able to explain in more personal detail how home haemodialysis works and what the drawbacks and positive parts were to it.
What was especially important to me was having someone non-judgemental to talk to, who understood what worried me. The chance to actually talk about things properly in “non-doctor speak” was so rewarding and was extremely helpful.
**Peer support recipient who was supported by Martin (pictured)**
## **Patient Support Services**
## **Emotional support thorough our dedicated free Counselling service**
With resources for psychosocial support in the NHS under more pressure than ever, our specialist renal counselling service offers a lifeline to those meeting the challenges of living with CKD. The people we support continue to express great relief and appreciation that they are able to speak to professional counsellors who have a good understanding of this gruelling and cruelly uncertain disease. Our service offers Zoom, Teams, WhatsApp or telephone counselling sessions; we’re happy to use whichever channel suits the person we are supporting.
Demand for our service remains high, with over 1,500 counselling sessions delivered in 2024, despite not having the benefit of a full complement of counsellors. This undoubtedly impacted the number of patients we were able to support, but we were able to welcome new counsellors to the team towards the end of the year and have already begun to redress the deficit.
In response to the growing demand for psychosocial support we are exploring different ways in which we can empower people to manage their emotional wellbeing and build personal resilience. A successful group session pilot carried out this year demonstrated that a counsellor-facilitated online group setting delivers real benefits to people presenting with common challenges, such as managing anxiety. Feedback from participants highlighted how accessing a safe space for sharing experiences and peer networking was beneficial to their confidence and improved feelings of wellbeing. In future we look forward to welcoming new clients into forums to address a variety of common challenges.
## **In 2024 we ran**
1,544 counselling sessions, **supporting 273 people affected by kidney disease**
**----- Start of picture text -----**
24
**----- End of picture text -----**
## **“**
**Our counselling team are exploring different ways in which we can empower people to manage their emotional wellbeing and build personal resilience. We’re looking at how we can deliver more counsellor facilitated group online sessions after a successful pilot as feedback highlighted that sharing experiences and networking with peers was beneficial to building confidence and improved feelings of wellbeing**
**Jackie Pilcher, Lead Counsellor, Kidney Care UK**
**----- Start of picture text -----**
25
**----- End of picture text -----**
## **Patient Support Services**
## **Patient grants to help people with kidney disease live life to the full**
Since the Charity’s inception, our patient grants service has been there to help people to navigate the challenges of living with kidney disease and the impact it can have on every aspect of your life. We continue to be proud to offer grants to patients, when sometimes just a little financial support can make a huge difference - whether they need a replacement fridge-freezer or a respite break away from the routine of treatment. It is heartening to see that, after the pandemic, our community are now feeling more confident about taking much-needed breaks, with nearly twice as many requests for assistance with holidays.
We provided a holiday grant of £480 to help Sharon and her husband have a short break with their grandchildren. The chance to have a few days away making memories is priceless.
**“Thank you very much for a fantastic holiday. Even if it was just for a weekend, it made a difference to me because being on dialysis it’s hard to live a normal life. I’m so grateful to Kidney Care UK. Sharon In 2024 we gave** £917,621
**to people affected by kidney disease, the highest number of grants and amount we’ve awarded in the last decade**
**----- Start of picture text -----**
26
**----- End of picture text -----**
## **Individual patient grants given in 2024**
**Holiday grants increased by** 69% **compared to 2023, as people’s confidence in travel returned.**
**----- Start of picture text -----**
27
**----- End of picture text -----**
## **Patient Support Services**
## **The chance to have a break, through the Kidney Care UK Dialysis Freedom service**
We continued to work extremely hard to enable as many patients as possible to access dialysis away from their regular hospital unit so that they can have a holiday in the UK, attend events, work, and visit family and friends. We received 2,236 requests for support in arranging Dialysis Away From Base (DAFB) in 2024 and were delighted to be able to confirm bookings for more than 1,000 patients (1,091).
Considering the limitations of access to DAFB across the UK, we are still managing to help hundreds of patients every year. As well as support to make a booking, we often give patients and home units advice and guidance on the DAFB process, the options available, funding, insurance and much more.
DAFB in the UK is still limited, mainly due to capacity and staffing within units. We currently have 41 units across the whole of the UK considering DAFB and 80 units considering requests via the swap scheme only (which is when one of their own patients is away, thus utilising an ‘empty’ space). With every booking we make (unless a home patient), we request that the travelling patient’s slot be made available to our ‘swap scheme database’ to try to improve DAFB places. For some areas in the UK, this is the only way to access space.
We’re pleased to say that 2024 has seen the highest positive answer for the swap scheme postpandemic.
**We had 924 requests for Dialysis Away From Base confirmed and booked in 2024 And 167 bookings made in 2024 for travel in 2025**
**----- Start of picture text -----**
28
**----- End of picture text -----**
## **“**
**It was all very well organised, both caring and professional. It was easy to arrange and the person I spoke to at Kidney Care UK Dialysis Freedom explained everything that I needed to do. The holiday centre was excellent, very friendly and my husband felt at ease during his dialysis treatment. Thank you very much, we couldn’t ask for anything better. Kidney Care UK Dialysis Freedom service user**
## **Patient Support Services**
## **Launch of free dedicated Support Line service providing reassurance and trusted advice**
Providing valuable information and trusted advice from our knowledgeable team, the launch of the Kidney Care UK free Support Line in August 2024 has transformed the experience for anyone seeking support for the challenges of living with CKD. In its first few months of operation, the Support Line has provided information and reassurance to 3,750 people.
The Support Line offers a friendly ear to listen to concerns, answer queries and to refer on to other services should the caller need further help, reassuring patients that talking to someone who cares and understands what it is like to live with kidney disease is just a call away.
Patients have told us that the service has:
- helped them feel less isolated with their diagnosis
- given them a better understanding of kidney disease
- provided access to a whole range of support to help them
They have also told us that their attitude towards their diagnosis has improved because of the positive conversations they’ve had with our team.
Looking forward, we are excited to build on the successes of the Support Line service and to help more kidney patients and their loved ones needing assistance.
## **In 2024 we supported**
## 3,750 patients
**and loved ones through our Support Line**
**----- Start of picture text -----**
30
**----- End of picture text -----**
Mary* called the Support Line. She has CKD stage 3b. Mary struggles to talk about how she is feeling, has financial difficulties and is worried about the future.
**“ Thank you so much for everything. I really felt heard and appreciated all the advice. Talking to you has been a massive blessing and helped me understand more about my kidney disease. I was looked after so well, many thanks.**
**Mary**
## **Patient Support Services**
## **Supporting young adults through our online community and residential weekend**
Kidney disease is especially difficult for young people at what is already a particularly challenging time in their lives. Having the opportunity to interact with other young adult patients is crucial for those who are transitioning from paediatric kidney care to an adult unit. It allows them to “see where they are going” and learn from slightly older peers who have had a successful and positive transition experience and who are building good working relationships with their new kidney teams, with a positive outlook for the future.
In January 2024 we extended membership of Kidney Care UK’s National Young Adult Kidney Group to young people aged 16 and 17 years old. We now offer support to young adults aged 16 to 30. We are working to improve the support we provide to our younger young adults, ensuring it’s age appropriate and easily accessible.
To supplement the advice and information provided by our 1,200-strong Facebook group and the work of the Peer Support team, we have been able to offer a series of webinars to group members in 2024. Requested by members of the group, these sessions have been on the subjects of work and employment, anxiety management and fundraising to support Kidney Care UK.
The webinars have created space for young people to ask questions in a supportive environment, as well as to contribute their own experiences and expertise as speakers or panel members.
In September 2024 we hosted our largest Young Adult Residential Weekend yet, with an amazing 89 young adult participants from England, Scotland, Wales and Northern Ireland travelling to Mount Cook Adventure Centre, ready to take part in a fun-filled weekend of outdoor activities, workshops and relationship building with peers from across the UK. Over half the group were first-time attendees, which is testament to the success of the weekend and the strong reputation it has developed.
**----- Start of picture text -----**
32
**----- End of picture text -----**
Shuaib joined the Young Adult Kidney Group in 2020, looking for support and a community to be part of. Since then, he has also taken advantage of opportunities to give something back to our community. He’s a peer supporter, residential weekend volunteer and has established a small group specifically for male members.
## **“**
Having experienced this journey as a young adult in 2023 and then as a Peer Support Volunteer in 2024, I find this residential weekend to be a heart-warming reminder of the strength found in community. Connecting with resilient young adults facing kidney disease made every moment inspiring and deeply rewarding.
**Shuaib In 2024 we had** 89 **young adult residential weekend attendees, the largest ever cohort of young adults attending the residential weekend**
**----- Start of picture text -----**
33
**----- End of picture text -----**
## **Patient Support Services**
## **Patient information: providing patients with accessible, trustworthy and empowering information**
Our patient information service – a critical element of our service portfolio – built on its Patient Information Forum (PIF TICK) accreditation in 2023 and saw unprecedented demand in 2024, our busiest year yet for patient information distribution. This growth was made possible by a move to outsourced fulfilment and online ordering through the new website, streamlining the ordering process and ensuring that most orders are sent out within a week. The team were extremely busy, fulfilling 317,515 leaflet requests from 2,433 clinical settings across our suite of more than 50 brochures and leaflets. Overall demand grew 100% year-on-year (in 2023 we fulfilled requests for 158,922 leaflets).
In 2024 we saw continued growth in requests for our resources, both in print and online, as well as completion of the redesign and update work started in 2023. Working with the UK Kidney Association (UKKA), we completed our review of all 56 titles and are delighted that they are all now updated and PIF TICK accredited, providing reassurance of their quality to patients and professionals.
Healthcare professionals are increasingly using our patient information materials to support and empower patients in understanding their kidney disease. These resources help individuals make informed choices about their treatment, enabling them to take a more active role in their care. Looking ahead we will continue to expand our range of leaflets and work with healthcare professionals to provide greater access to our materials, putting patients at the heart of what we do.
## **In 2024 we sent out**
317,000 **patient information leaflets**
**----- Start of picture text -----**
34
**----- End of picture text -----**
**“ My colleague has been corresponding with you for your CKD literature. It is really fantastic, easy to read and laid out well. I talk through the main chronic kidney disease information at events with local residents before they take it away. Healthcare professional from Sutton Primary Care network**
**----- Start of picture text -----**
35
**----- End of picture text -----**
## **Patient Support Services**
## **Kidney Kitchen: ensuring delicious food is back on the table when you have kidney disease**
When we think about health beyond medicine, the success of the Kidney Kitchen continues to grow, with 378,000 unique visitors coming to the website for dietary information and advice – a 35% increase on 2023 traffic. This also translates into total print order numbers across our four Kidney Kitchen recipe magazines, which now exceed 40,000, a superb achievement from a standing start back in 2021 and an indication of the level of demand that exists for high quality, trusted dietary information when you are coping with the demands of a restrictive kidney diet.
We welcomed more guest chefs into the kitchen to create kidney-friendly dishes with Chef Ripley, notably Lai Man and her father, Kim. The ‘Wonton with tossed noodles’ recipe then formed part of a Kidney Kitchen masterclass Chef and Lai gave at the Young Adult Kidney Group Mount Cook Residential Weekend to an enthusiastic group of young adult kidney patients. And once again this year, the entire Mount Cook Young Adult Weekend menu was based on recipes provided by the Kidney Kitchen.
**“** I am a huge Kidney Kitchen fan; I find the recipes really helpful with managing my diet and I love exploring new recipes. Saturdays are my Kidney Kitchen days at home, and it’s my day to cook for everyone else.
**Young chef Charlie Friedland, who cooked in the Kidney Kitchen with us**
## **In 2024 there were**
## 378,000
**unique visitors coming to the website for dietary information**
**----- Start of picture text -----**
37
**----- End of picture text -----**
## **Patient Support Services**
## **Giving people with kidney disease access to the best online information, tools and support**
Our digital engagement went from strength-to-strength in 2024. We had a fantastic 1.49 million unique visitors to the website, up from 1 million unique users in 2023 (a 42% increase year-on-year), due to the excellent efforts of our Web & Digital team who developed digital content and hubs to promote our support services. Looking back to 2021, we had a total of 673,160 unique visitors to the website. Put simply: the growth and profile of the Charity is increasing sharply because of our desire to ensure that everyone who could benefit from our support is aware and able to access it. Subscriptions to our email newsletter grew to a record 28,838, up from 16,810 at the end of 2023 (a 72% increase).
Accessibility, ease of use and eye-catching design continue to drive our content publishing schedule, with approximately 70% of our website traffic now on mobile devices. Our email programme allows us to communicate with people who have signed up to hear from us and share information and news that is useful and relevant for everyone affected by CKD. In 2024, we emailed our mailing list every week with updates about treatments, policy campaigns, patient services and fundraising and volunteering opportunities.
In February we updated the infoKID website for the parents and carers of babies and children with CKD, produced in partnership with the British Association for Paediatric Nephrology. In July we produced a new website for our Shared Haemodialysis Care programme, which engages patients as active partners in their treatment.
New digital tools developed in 2024 make it easy for people to understand their risk of developing kidney disease, check their benefits entitlement and contact their MP. With almost 120,000 completions in 2024, the Kidney Health Checker (https://kidneycareuk.org/kidney-health-checker/) is the cornerstone of our #BloodyAmazingKidneys awareness campaign and continues to drive incredible engagement, educating people about their kidney health and helping them discuss their CKD risk with their GP. You can read more about this campaign on page 50.
The free Kidney Care UK Benefits Calculator (https://kidneycareuk.entitledto.co.uk/) allows our users to understand the benefits and financial support they may be entitled to when they are living with kidney disease. In 2024, 5,510 users completed a Benefits Calculator calculation. Our free PIP Helper offers step-by-step guidance from the Kidney Care UK Patient Support & Advocacy team for people who are applying for Personal Independence Payment (PIP). The Helper had 3,835 users in 2024.
**----- Start of picture text -----**
38
**----- End of picture text -----**
**----- Start of picture text -----**
“
**----- End of picture text -----**
**[The website information] reads well, is simple to understand and not scary. It’s clear and informative. I wish I’d been directed to read this [when] I was diagnosed. I got a letter from a GP... and my first Google search told me I was going to die! Feedback received via email**
## **In 2024 there were**
1,499,645
**users of the Kidney Care UK website**
**----- Start of picture text -----**
39
**----- End of picture text -----**
## **Patient Support Services**
## **Educating and informing people through our regular Kidney Matters magazine**
Our 2023 Kidney Matters readers survey clearly demonstrated a request for ‘more of the same please’ – more insightful, lived patient experiences, more trustworthy healthcare professional advice and more signposts to the help and support available from Kidney Care UK.
We started 2024 with a new, talented and ambitious Kidney Matters design and editorial team with a remit to enhance the magazine’s appeal to everyone affected by kidney disease. In the last twelve months this approach successfully stimulated an increase in individual sign-ups to receive Kidney Matters at home to 12,188 (December 2024 data) – an increase of 39% on 2023.
As the leading kidney patient magazine in the UK, Kidney Matters also works hard to cultivate relationships with related healthcare charities. One such charity, the PKD Charity, supported a piece in the autumn issue on the use of tolvaptan, a drug which can help maintain kidney function in some patients with polycystic kidney disease (PKD). A successful inter-charity collaboration acknowledged by Jane Pugh, PKD Charity Communications Manager, “I wanted to extend my sincere thanks for the outstanding coverage. It’s rare for PKD to receive such in-depth attention, and raising awareness is crucial for improving education and advancing research for the thousands affected by this condition. Thank you again for your continued support.”
**----- Start of picture text -----**
40
**----- End of picture text -----**
## **In 2024 there were**
## 12,188 **individual sign ups to receive Kidney Matters magazine**
One of the most striking and heart-warming stories we covered in Kidney Matters was that of a young Ukrainian man, Mykola, who, forced to flee his war-torn home where accessing safe dialysis was no longer possible, trekked unaccompanied across Europe facing unimaginable difficulties en route, to reach the safety of Scotland – the place he now considers home. Mykola is now an active member of our Kidney Care UK Young Adult Kidney Group (YAKG) and joined us at the 2024 Mount Cook YAKG residential weekend.
**----- Start of picture text -----**
41
**----- End of picture text -----**
## **Working in partnership to improve the**
Since 1975, Kidney Care UK has been working in partnership with health and care professionals, as well as patient organisations, to support service improvements and innovation in patient care and to ensure that the views and involvement of patients are at the forefront of all local and national service developments and quality improvement work.
## **Investing in improvements to kidney care through our Hospital Grants programme**
Over the last fifteen years the charity has provided over £10 million in funding for 70 hospital renal units around the UK, as well as providing grants to patient organisations, professional associations and other key projects that support improvements to access and quality of patient care services. In 2024 our ongoing investment commitments stood at around £500,000, and in 2024 we agreed to award a further 44 new grants totalling an additional £456,636. Highlights included:
## **A new holiday caravan for South East Scotland KPA**
We have replaced the Caravan at the Berwick Holiday Centre so that members of the South East Scotland Kidney Patient Association (SESKPA) and Fife Kidney Patient Association are able to get a much-needed break.
## **An exercise bike to help patients at Shrewsbury and Telford NHS Trust**
This machine allows haemodialysis patients the opportunity to undertake exercise whilst undergoing treatment. If assessed to be suitable these individuals will have a moderate exercise plan developed to help them maintain strength and health over a number of months.
## **Helping 18 teams take part in the 2024 Transplant Games**
As well as providing funding to support 18 teams from across the UK to attend the British Transplant Games in Nottingham, we were once again one of the lead sponsors of the Games.
## **A national partnership with the UKKA to improve early care**
A three-year national programme, in partnership with the UK Kidney Association, to improve Advanced Kidney Care Clinics.
**----- Start of picture text -----**
42
**----- End of picture text -----**
## **Investing in a major national change programme through our Advanced Kidney Care Clinics project, Transform AKC**
A significant investment via our Hospital Grants Programme has been the development of the Advanced Kidney Care Clinics project, Transform AKC, run in partnership with the UKKA. This is a major three-year national programme of change, with an aim of improving equity of access to the highest quality care and driving system wide, sustainable change in the support and preparation of patients as they approach kidney failure.
The project will see five pilot sites from across the UK recruited to create an Advanced Kidney Care toolkit and patient support package which puts the patient at the heart of the clinics, as well are creating a community of professionals who can champion change. Through a series of webinars, face-to-face summits and group working, the project aims to standardise the variation in Advanced Kidney Care across the UK and facilitate change.
The programme has major ambitions and aims to:
- Form a multidisciplinary Advanced Kidney Care (AKC) working group to harness the collective knowledge of AKC clinical leads across the UK.
- Develop an operational structure that provides the opportunity for lead practitioners and organisations engaged in the delivery of Advanced Kidney Care Clinics to input and be part of this national project.
- Define the elements of ideal care from a patient and carer perspective and unmet need including psychosocial.
- Recruit renal units to be part of the QI programme to pilot change ideas on the ground.
- Redesign the ideal care pathway and service specification, supported by designing and testing tools and resources for routine measurement of symptoms and unmet need.
- Create a toolkit of resources for patients and staff to promote shared decision making and patient centred servicecare.
- Provide staff training to support provision of ideal care including as psychosocial “first responders”.
**----- Start of picture text -----**
43
**----- End of picture text -----**
## **Putting the patient voice at the**
## **The Kidney Patient Reported Experience Measure (PREM)**
We believe the patient voice must be at the heart of quality improvement, which is why the Kidney Patient Reported Experience Measure (PREM) survey is such an important piece of work. The 2024 kidney PREM was the ninth PREM survey we have released, in partnership with the UK Kidney Association (UKKA) and supported by the University of Hertfordshire.
The survey was completed across eight weeks in autumn 2024, and asked people to rate 13 key themes with a score out of seven, as well as allowing patients to add their own personal comments on the care they receive, which we ensure are fed back to their healthcare team. This year we received the highest number of responses since 2019, with 13,347 completions. Of the 13 thematic questions, the questions about privacy and dignity received the highest score (indicating approval), and transport received the lowest score.
As well as helping us see how units are performing year on year, it is crucial that the feedback we receive is actively utilised by units. Therefore, we introduced “you said, we did” posters, and encouraged units to display these on their wards to show their patients how they are listening to their feedback and using it to improve the care provided.
**----- Start of picture text -----**
44
**----- End of picture text -----**
## **In 2024** 13,347 **PREM surveys were completed, the highest completion rate in five years**
**----- Start of picture text -----**
45
**----- End of picture text -----**
## **Putting the patient voice at the**
## **Empowering patients to take more control and play a shared role in their care**
Kidney Care UK has been instrumental in driving and supporting greater uptake of Shared Haemodialysis Care since 2017, and we remain committed to helping empower patients to be in more control, become partners in their own care and improve their confidence and health outcomes.
Our funding and support for the national accredited training programme continues to train hundreds of healthcare professionals and teams right across the UK and following the publication of the NHS GIRFT (Get it Right First Time) report the interest in Shared Care and the development of a greater learning culture in units has significantly increased.
In 2024 we brought the programme and resource in house and hosted it on a new, bespoke website, as well as developing a distinct Shared Haemodialysis Care brand look and feel. We are pleased with the growing traffic on the Shared HD Care website with 1,400 unique users and 5,044 page views since launch (24 July 2024). We will continue to update and develop the training resources with the new branding, supporting the growing community of practice and continue promoting the Shared Care course and resources to healthcare professionals in 2025.
**----- Start of picture text -----**
46
**----- End of picture text -----**
## **Empowering patients to take more control and fit their healthcare around their lives through the national DAYLife project**
As a founding member of the national DAYLife programme (Dialysis at Yours, Life Fulfilled), 2024 saw us continue to work in partnership to increase the rates of home dialysis in the UK, giving patients greater control over their care and improving their quality of life. Our aim remains for all kidney centres to achieve a minimum of 20% of their patients on home dialysis.
The DAYLife project continued in 2024, and we were delighted to welcome the National Kidney Federation (NKF) as a new partner in the programme, joining ourselves, the UKKA and Fresenius Medical Care. Following feedback from patients and healthcare professionals, we established four core national workstreams, all designed around the key elements needed to support greater levels of home care:
- Shared Decision Making
- Psychosocial Support
- Peer Support
- Shared Haemodialysis Care
The programme included a Home Dialysis Summit and webinars for both health professionals and patients promoting shared care and peer support. The DAYLife Knowledge Hub was created and is now a central resource for all healthcare professionals to help them promote home therapies and discuss ideas with others in the field.
**----- Start of picture text -----**
47
**----- End of picture text -----**
## **Policy and Campaigns**
## **Ensuring patients’ views are effectively represented and campaigning for better care**
## **Championing the issues that matter most to our kidney patient community**
The patient voice is at the heart of everything we do. It is the most important part of our work to influence and campaign for change. We’re fortunate to have many people willing to share their perspective and experience of chronic kidney disease and kidney failure. These people include patients, carers, family members and living kidney donors. Their insights are critical, providing credible and authentic insight that shapes and informs our work, and Kidney Care UK engages with thousands of patients every year.
## **Influencing policy and campaigning for change**
Our Policy team is dedicated to making sure the voices of kidney patients are heard by politicians and policy makers, to help them understand the challenges kidney disease can bring and develop the policy framework that drives health and care practice in our NHS and social care services and interventions. Whether bringing people with kidney disease to our national Parliaments or seeking their views on key issues like prevention of CKD, our campaigns are fuelled by what the kidney community tell us they need. With so much change in the health service it was a busy year with work across all four UK nations and themes covering early diagnosis and prevention, organ donation and transplantation, transport and the cost of living.
## **Home dialysis – getting your energy costs repaid**
In February 2024, following our campaigning, the Scottish government introduced national guidelines for energy reimbursement for home dialysis in Scotland. Jenni Minto MSP, Minister for Public Health and Women’s Health, made the announcement at a roundtable on the cost-of-living crisis for people with CKD in Scotland, led by Kidney Care UK and hosted by Miles Briggs MSP. This was followed in October by confirmation that, as a result of our campaigning, future reimbursement payments in Northern Ireland would cover peritoneal dialysis as well as home haemodialysis.
## **Improving transplantation experiences and organ donation rates**
With the waiting list at a ten-year high, it is vital that increasing demand for transplants is carefully considered by the NHS and government. Our Transplant Care in the UK report, based on 670 survey responses from people affected by kidney disease , provides a unique insight into the patient experience of the kidney transplant journey and an important evidence base for our influencing work. It showed up
**----- Start of picture text -----**
48
**----- End of picture text -----**
very clearly the wish for and lack of psychosocial support – we have taken these findings to government to help them to understand why change is needed.
In December we took 22 people affected by kidney disease to Parliament for our Organ Donation Parliamentary Reception, held with NHS Blood and Transplant and hosted by Florence Eshalomi MP, who spoke about her mum’s 11 years on dialysis. Over 60 MPs and peers attended to hear first-hand about the impact of the disease, the transformation a transplant can bring and the challenges of waiting for a suitable organ. The Health Minister Baroness Merron attended and encouraged people to sign the organ donor register and talk to their family about their decision. She spoke highly of Kidney Care UK, saying: “You always see patients as people, not as conditions to be treated, and I commend you for that”. We spoke of the need for earlier identification and treatment of CKD, so fewer people would face kidney failure in the future.
## **“**
CKD seems to be the ‘forgotten’ disease and hopefully by us engaging with the MPs in attendance we brought the message about the importance of organ donation a lot of publicity. My transplant has enabled me to have a life and see my children and amazing grandchildren growing up and have the ability to work and do all the normal everyday things that people take for granted.
**Lesley Cole, who attended our reception in Parliament in December 2024**
## **Our Bloody Amazing Kidneys**
The autumn of 2024 saw us launch our first ever national awareness campaign, our Bloody Amazing Kidneys campaign. This focused on the amazing job our kidneys do to filter our blood and keep all our organs working but also shared the vital message that you can lose up to 90% of your kidney function without realising.
The aim of the campaign was to use social and digital tools and channels to raise awareness of CKD amongst at risk groups in the UK to improve rates of early identification and diagnosis. The campaign encouraged people to take our online health checker and see if they were at increased risk of developing chronic kidney disease, and also provided information and advice to support them to approach their GP. We also had a small number of posters displayed in shopping centre and service station washrooms as well as some adverts at bus stops and in Candis magazine, and provided all our partner organisations with posters they could display at their offices.
In 2024 we secured more than 300 pieces of media coverage on the campaign, and the posters were scanned over 1,500 times. We also secured a slot in the NHS Primary Care Bulletin which is sent to over 25,000 healthcare professionals and this resulted in more than 100 medical practices sharing the campaign on social media and with their patients.
Our target was to achieve 10,000 completions of our Kidney Health Checker within the first month of the campaign. We hit that target within a week; after the first month 110,000 people had completed the Checker with around 50% identified a being at increased risk. By the end of 2024, 118,935 people had completed the Checker.
**By the end of 2024** 118,935 **people had completed the Kidney Health Checker**
**----- Start of picture text -----**
50
**----- End of picture text -----**
The campaign has garnered interest across the world, with ongoing discussions with our charity counterparts in Australia, New Zealand, Turkey and Spain taking place. Closer to home, the initial response to the campaign has led us to have conversations with various Kidney Networks and Commissioning Boards in the NHS and we’re excited about the doors this may open in terms of reaching more people who may be at risk of kidney disease and encouraging them to learn more, check their risk and if appropriate get tested to ensure an early diagnosis.
**----- Start of picture text -----**
51
**----- End of picture text -----**
## **Our patient advisory group (PAG)**
Established over 10 years ago, and currently with 17 committed patients, this group has grown over the last two years, attracting an increasingly diverse representation of patients across the UK. The PAG meet virtually, up to four times per year, with one in-person meeting. Over the last 12 months they have specifically supported the Charity with:
- Feedback to the British Transplant Society on cardiac testing.
- Feedback on the use of digital technologies for the Annual Dialysis Conference.
- Feedback on our #BloodyAmazingKidneys campaign.
- Feedback to a study looking at patient weight loss in transplant services.
- Participating in a workshop consultation as part of NHS 10-year plan.
Our PAG members are often invited to represent the Charity outside of meetings which might include providing patient representation to NICE (National Institute for Health and Care Excellence), attending specific Kidney Care UK events, focus groups for patient information or national conferences, and to support collaborative quality improvement work in the NHS.
## **PAG is now**
10 years old **and has 17 members, growing 40% in the last two years**
**“** Thank you for the opportunity and allowing me to be part of making a real change. It was great to hear the views of other kidney warriors and being able to relate to the issues they face. I’m looking forward to the next meeting and what it holds.
**Harkaran, PAG member**
##
**----- Start of picture text -----**
52
**----- End of picture text -----**
## **Raising standards and increasing patient involvement**
The Kidney Patient Involvement Network (KPIN) was launched with Kidney Care UK in 2019, to increase the impact of the patient and carer voice and to establish a network to share good practice, offer peer support, and provide training and support to empower more patient leaders. KPIN continues to grow and is the ‘go to’ network for those in the kidney community seeking wider patient representation within their projects, committees, research or service re-design.
With **over 300 members** (patients, carers and professionals), supported by **two trained KPIN facilitators** , KPIN continues to grow, develop and flourish. Feedback from professionals and patients involved highlights that KPIN provides a quick and excellent service and offers well trained and supported patient involvement.
Over the last 12 months KPIN facilitators have focused on supporting the clinical networks embedding the patient voice, identifying patients, offering peer support and training to increase patient involvement locally.
**----- Start of picture text -----**
53
**----- End of picture text -----**
## **Managing our charity as effectively and efficiently as possible**
## **Ensuring infrastructure can support our accelerated growth**
With the accelerated growth of the Charity in 2024, our IT provision has been vital in ensuring our workforce are able to do their jobs and support more people with kidney disease than ever before. With most staff working on a hybrid working pattern, and many of our patient support services teams working entirely remotely, we need to ensure our IT platforms are stable, have integrity and are secure. Our HR function has also adapted to accommodate the growth of the Charity, and the range of working models across office based, hybrid and fully remote working patterns.
## **Data and IT support**
The planning for the launch of our new database system in 2025 dominated a huge amount of our time in 2024. This is a substantial programme of work and underpins much of our new approach to efficient and digitally supported processes. The implementation phase commenced in September and will run through to March 2025.
We renewed our Cyber Essentials accreditation in 2024, giving reassurance to those sharing information with us that we have the appropriate systems in place to keep their data safe. In January 2024 we updated our device protection by upgrading our antivirus and web defence protection; this not only enhances our defences but will enable us to meet the new requirements for cyber insurance when we complete our annual renewal. In order to maintain the security of our systems, external penetration testing was completed by Cyber Armed Security.
## **Looking after our people**
We welcomed 48 new team members across various departments, taking our headcount from 75 at the start of the year to 110 at the end of the year, an increase of 47%. To make the induction process as smooth as possible in this period of growth, we also implemented a new streamlined onboarding program, ensuring new members of staff are able to hit the ground running and are given all the tools they need to be able to do the best job they can from their very first day.
We’ve encouraged our staff to take advantage of apprentice qualification funding and have several staff signed up to coaching and management qualifications. This not only benefits the Charity, it’s also a fantastic opportunity for our staff to benefit from extensive training to help develop their professional career. In 2024 we also embedded our new staff benefits scheme, which includes mental health support, financial advice, wellness activities. We also offer an enhanced employer pension contributions of 8%,
**----- Start of picture text -----**
54
**----- End of picture text -----**
flexible working opportunities, retail discounts and a health cash back plan giving staff access to cash following expenditures on dental, optical, physiotherapy and scans such as MRI scans.
Our staff survey in April gave us some clear guidance on what the team at Kidney Care UK view as the most important areas for us to focus on. Despite the challenges that come with growth we were pleased that we actually increased our Staff Engagement Index score from 82% in 2023 to 85% in 2024. However, we are determined not to rest on our laurels and established a new National Staff Engagement Group, made up of staff from all levels and departments, to work with us to build action plans to improve our ways of working on the things that matter most to our people.
## **Kidney Care UK had 75 members of staff at the beginning of 2024, growing to 110 by the end of the year: growth of 47%**
## **“**
I would recommend Kidney Care UK as a place to work, and I feel that the Charity values their employees. I am proud to be part of the Kidney Care UK team; the passion and commitment from everyone is inspiring. **Kidney Care UK member of staff***
##
## **Fundraising**
## **Inspiring more people to donate to the Charity so we can support more people affected by kidney disease**
2024 was a record-breaking year for the Charity’s income generation with £1 million more being raised through donations and legacies, grants, corporate partnerships and trade in 2024 than in 2023 – an increase of 43%. We receive no government funding and therefore rely on support from our kind and generous supporters to enable us to provide patients with the support they want.
## **Fundraising income 2024**
**----- Start of picture text -----**
56
**----- End of picture text -----**
Fundraising income growth
In 2023
In 2024
£2.340.889 £3.350.776
fundraising
incomegenerated
fundraising
incomegenerated
2023
2024
Donatkjns from Indlvlduals
£181.257
Donatlons In memory
01.220
Logw in¢om•
657
£226A40
Corporate fundrnising
,210.189
Challwge wents
£610,233
Commyn•tyfufidrai$ing
£202J08
Othèrtradlnglneomo
18a
£4SS10
57
## **Fundraising**
We believe in working together with others to ensure people with kidney disease can benefit, this is particularly true with our work with partner organisations through our corporate partnerships. The team secured a record income of £1,210,189 from more than 30 partners. We won our first partnership award with Anglian Water at the Collaboration Network Awards 2024 and companies have built new teams, and new tariffs (including the Anglian Water medical tariff being introduced in April 2025 which is a first in the industry) due to working collaboratively in partnership with us to better serve their customers. This represents tangible change for the kidney community above and beyond financial contributions.
From the Kiltwalk in Scotland to the Cardiff Half Marathon and treks across the South Downs, people across the country have embraced their personal challenges to support us. Record-breaking Hannah and Ede cycled from Land’s End to John O’Groats on tandem bikes, while 90-year-old Trevor raised over £1,500 by cycling 340 miles on his exercise bike. These efforts exemplify the passion and determination of our supporters, driving our success this year.
Our second annual Dog Walking challenge was a huge success, with participants and their four-legged friends walking 32.5 miles over October, raising £15,000. Across 2024, 600 people (and 142 dogs!) took part in various events, raising over £600,000 (an increase of 29% on the year before). One particular standout was the London Marathon 2024, which generated an impressive income of over £242,000.
## **In 2024 we raised** £3,350,776
**Thank you - we can’t do what we do without you!**
**----- Start of picture text -----**
58
**----- End of picture text -----**
**The Legenderry Motor Show is a fun family day out and, since 2022, has raised almost £34,000 to support people across Northern Ireland living with kidney disease. “**
**Kidney Care UK has been proud to be the chosen charity for Legenderry Motor Show for three consecutive years and has built a strong and lasting relationship with the organisers who put their heart and soul into this motoring spectacle.**
##
**----- Start of picture text -----**
59
**----- End of picture text -----**
## **Fundraising**
**There was an increase of 36% in the number of individual giving donors**
**Our largest legacy left in 2024 was for £150,000**
**£101,220 was donated in memory of a loved one**
**£769,620 was left to the Charity in gifts in Wills**
**----- Start of picture text -----**
60
**----- End of picture text -----**
**£1,210,189 was raised from more than 30 corporate partners**
**We won our first partnership award with Anglian Water at the Collaboration Network Awards**
**Our Community Fundraising team raised £202,308, a 39% increase on 2023**
**More than 600 people (and 142 dogs) took part in a walk, run, cycle or adrenaline fueled activity in 2024, raising more than £600,000**
**Our London Marathon team raised £242,000**
**We secured £226,440 through Trusts and Foundations, an increase of 18% compared to 2023**
**61**
## **Looking ahead to 2025**
## **Our aims and goals**
- We will continue to extend our reach and engagement across the UK, so patients are aware of the Charity and are able to access our support, with a focus on increasing our profile in the devolved nations and with underserved communities.
- We will continue to prioritise supporting our staff with a clear focus on wellbeing and development. Working with HR, managers and our newly formed Staff Engagement Group, we will develop and implement an employee wellbeing plan, a structured approach to management training and personal development, and conduct a review of our core values and behaviours.
- As part of our digital transformation plans, we will implement a new CRM database to reduce manual administration for our staff and improve operational efficiency and continue to move towards a fully cloud based operation.
- We will seek to secure the funding that allows us to further expand our Patient Support & Advocacy service across the whole of the UK ensuring equity of access for patients, as well as embedding our new peer support and support line services within our service portfolio, with the goal of providing direct support to 10,000 patients.
- We will review and refresh our five-year strategy, to ensure we remain focused on those issues and themes that are of the highest importance to kidney patients and where we can make the greatest difference to the quality of patients’ lives.
- We will conduct a full strategic review of our partnerships and hospital grants programme to ensure it remains aligned with the Charity’s core aims and targeted where we can make the biggest impact on the quality of services and patient outcomes.
- We will continue to raise our profile and levels of support and engagement in Scotland, Wales and Northern Ireland, so we are assured our approach is fully befitting a truly UK patient charity, including a partnership with Kidney Wales to recruit a dedicated policy officer for Wales to raise the power of the patient voice and influence policy at the heart of government.
- We will continue to work to increase the power of patient voice and involvement, with a particular focus on our Shared Care and national DAYLife Programmes, so that true patient choice and empowerment allows more patients to take control and be partners in their own care.
**----- Start of picture text -----**
62
**----- End of picture text -----**
- We will continue to expand our patient information and education resources, packaging our information around patient pathways, key lifestyle and quality of life domains and ensure that patients can get the information they need, when they need it and in a format they choose. This will include the launch of a range of Easy read formats to ensure that health literacy is not a barrier to patient care.
- We will significantly grow our Young Adult Service and move our online community to a platform that is best aligned to the community’s needs and preferences. We will continue to work in partnership with patients, young adult workers and youth workers to provide tailored support and information appropriate for individuals dealing with the specific challenges at their stage of life.
- We will continue to ensure that patients’ views are effectively represented, and voices heard at the heart of policy and practice in the UK and continue our campaign to increase the rate of early diagnosis and intervention for individuals at risk of chronic kidney disease.
- We will assess the support available to children, parents and young people living with kidney disease and identify opportunities to meet their needs through information, guidance and psychosocial support.
- We will inspire more people to donate to the Charity and grow our fundraised income, with a target to raise £5m in 2025 for our 50th anniversary year so we can support more families affected by kidney disease and meet the increasing demand for our services.
**“** Our dad was receiving renal care and battled for seven years, he’s no longer suffering with a disease that couldn’t be cured. As a family, we are devastated. We want our donation to help another family on their final journey with their loved ones. Writing this gives me a great sense of pride and happiness.
**Donation in memory of a father, grandfather and husband**
**63**
## **Our financial statements**
## **Financial review of the year**
The Charity has experienced its largest year of growth in 2024, with staff numbers increasing to 110 from 75 last year, the vast majority of this growth is in the Advocacy service funded through the Gas Distribution Networks for our Safe and Warm Programme. The Charity has considerably improved and expanded its services for patients and beneficiaries, supported by growth and diversification in our income streams. Our total income for the year increased by 35% to £4,123,556 (2023: £3,052,202), while total expenditure increased by 24% to £6,713,589 (2023: £5,429,930). The Charity benefitted from net gains in investments of £2,144,359 (2023: net gain £1,211,629) as a result of an upturn in investment markets throughout the year. Overall, the net reduction in the Charity’s funds totalled £445,674 (2023: a reduction of £1,166,099).
Income generated increased across a number of income streams, with corporate and event income performing particularly well, whilst we saw a small reduction in income from merchandise sales. Income generated after excluding investment and legacy income increased by 38% to £2,581,156 (2023: £1,861,784), this figure includes £941,285 (2023: £178,157) income from charitable activities and merchandise sales of £47,954 (2023: £55,122). This uplift reflects our strategic objective to support more patients and broaden our income streams. Notable funded projects include the Advocacy & Patient Services expansion (Safe and Warm; funded by our Gas Distribution Network Partners: Cadent, SGN, Wales and West Utilities and Northern Gas Networks) and the Money and Energy Service (funded by the British Gas Energy Trust).
Overall, our charitable activities expenditure increased by 26% in 2024, to £5,664,702 compared to £4,503,936 in 2023. We continued to experience an increase in the need for direct/one-to-one patient services, such as advocacy, counselling and direct patient grants. This is understandable in the wake of the cost-of-living crisis and the expansion of our service reach and awareness. This is in line with our strategy to improve the way kidney patients are cared for across the UK with access to the highest quality holistic care. We also continued to ensure that kidney patients had access to the most accurate, up to date patient information, in hospitals and online.
We continued to invest in our fundraising capability to sustain and advance our fundraised income in the future. Again, this is in line with our strategic aim to inspire more people to support our work, grow income and develop a mature fundraising portfolio, so we can do more to support our beneficiaries. We have seen positive results from our investment, and income has risen significantly, especially non-legacy income which performed particularly well. Expenditure on raising voluntary income increased by 21% to £927,384 (2023: £769,179) reflecting the ongoing expansion of our fundraising capability.
**----- Start of picture text -----**
64
**----- End of picture text -----**
As of 31 December 2024, our funds totalled £27,081,772 (2023: £27,527,446), of which £26,688,763 (2023: £27,131,956) is unrestricted. Restricted funds totalled £297,316 (2023: £305,303) and endowment funds £95,693 (2023: £90,187). Of the unrestricted amount, £26,200,000 (this includes tangible and intangible fixed assets with a net book value of £473,086) is set aside as a designated fund to deliver our grant giving programmes in perpetuity; the balance is free reserves which were £488,763 (2023: £431,956). The Trustees agreed that a transfer of £500,000 should be made from the designated fund to the general fund. The transfer was made to off-set the impact of the deficit; the Trustees believe that this is an adequate level required to generate sufficient income to cover the regularly occurring grants and running costs of the Charity.
The Trustees have an aspirational designated fund reserve policy of £30,000,000. The Trustees acknowledge that the current balance of £26,200,000 is below the aspirational target and that this is in part due to the fluctuation in the investments and as a result of the ongoing investment in the Charity’s growth. The Trustees are satisfied that £30,000,000 is appropriate and attainable. The Trustees are content that current reserves levels are sufficient.
## **Investment policy and performance**
At the end of the year under review, Cazenove Capital Management and CCLA Investment Management Limited (CCLA) managed the Charity’s dual investment portfolio split approximately 50%: 50%. The whole of the small Endowment Fund is also managed by CCLA. The funds are split with the CCLA COIF fund operating an active fund managed approach and Cazenove a passive fund solution to diversify the Charity’s investment risk profile. The Investment Managers have full discretionary powers within certain restrictions and limitations, as delegated by the Trustees, and they report to the Finance and Investment Committee on a regular basis. The Finance and Investment Committee and the Trustees continue to be supported by the advice of Enhance Group (UK) Limited, based in Jersey.
During the year, on behalf of the Trustees, the Finance and Investment Committee (the Committee) undertook a competitive tender of the investment portfolio and managers, with the assistance from the Charity’s investment advisors. The Committee carried out the review during May and June 2024 and put their recommendations to the Board in June 2024. The tender was underpinned by the following evaluation criteria: Performance, Process, People, Planet and Price. After concluding the tender, the Trustees agreed that the Charity should retain Cazenove Capital Management and replace Evelyn Partners Investment Management LLP with CCLA Investment Management Limited, investing in their COIF Charities Investment Fund (COIF Fund). The removal, appointment and onboarding process started in July 2024 and was fully complete by November 2024. The funds held by Evelyn Partners were managed as a segregated portfolio, while the COIF Fund is a pooled fund, therefore, to transition between investment managers, holdings in individual investments were disposed of, converted to cash
**----- Start of picture text -----**
65
**----- End of picture text -----**
and used to purchase units in the COIF Fund. Some of the investments were transferred “in specie” and then converted into COIF units. For this reason, there are material disposals and additions showing in the investment note (note 20) of the accounts.
Stock market conditions were fair throughout the year with the cooling of inflation and easing of interest rates. Equity markets performed well resulting in a realised and unrealised increase of circa 8% of funds under management, amounting to a £2,144,359 gain (2023: £1,211,629 gain). The Trustees appreciate that global markets are likely to remain volatile throughout 2025.
The investment objective is to achieve a long-term total return as a result of growth in capital and income derived from a diversified portfolio of investment assets with a moderate degree of risk. As of 31 December 2024, the Charity’s investments were 75% in equities, 11% in fixed interest, 11% in property and alternatives and 3% in cash.
Kidney Care UK’s investment policy stipulates there should be no direct exposure to tobacco stocks.
## **Reserves policy**
The Trustees have reviewed the Charity’s needs for reserves in line with the guidance issued by the Charity Commission. For the foreseeable future, the Trustees anticipate that there will be significant growth in the need for support of renal patients. This is driven by changing demographics and the increasing incidence of renal failure as a proportion of the population in the UK, along with government spending challenges for the NHS.
For the foreseeable future, within the parameters of its current policies, the Charity expects to be able to meet the needs for financial support of patients and their families. The Charity expects to be able to sustain its support for, professional, clinical and social carers, the development of services and facilities, and the provision of equipment for the better treatment of kidney patients and their families, and research into the effectiveness of those services and provisions.
Kidney Care UK readily re-deploys elements of its investments to fund posts, projects or research or for cash flow purposes. The Charity relies on investment income and capital appreciation to fund day-today expenditure in support of its primary charitable objects and continues to invest in its growth and transformation i.e. improving the quality of life of kidney patients. The Charity could not deliver the help needed to support its beneficiaries without its investment income and Kidney Care UK is therefore not at liberty to deploy invested funds elsewhere without potentially incurring a penalty to the future delivery of its primary objective. The Charity’s free reserves are £488,763 as defined in the SORP, which would cover about one month of expenditure. The Charity’s investments will remain an essential source of income to
**----- Start of picture text -----**
66
**----- End of picture text -----**
meet our charitable objects and can be drawn down as needed.
The Charity has set aside a core designated invested reserve fund, the income and capital appreciation of which, together with voluntary donations and income arising from other activities, will for the foreseeable future provide for the administration of the Charity, the needs of our “Objects”, and the depreciation of the purchasing power of resources by inflation. In addition, the Charity will seek to retain sufficient surplus resources to mitigate against the inherent volatility of holding investments. The reserves policy and level of the core investment funding is reviewed annually by the Board. Resources in excess of the Designated Reserve are retained as a General Reserve, which the Trustees will seek to apply appropriately over the short term.
## **Going concern**
The economic uncertainty caused by the changes to US trade tariffs, the ongoing war in Ukraine and the continued uncertainty in the Middle East does pose risk to the short-term value of investments in 2025. However, our approach remains to take a long-term view of our investments and we remain confident that the steps and processes we have put in place will allow us to ride out the continued volatility and support a sustainable growth plan. As a result, our Trustees have reviewed our financial position and plans along with our risk management in light of the current environment and have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the Accounting Policies.
## **Grant making**
Kidney Care UK makes grants to hospitals, to fund innovation and quality improvements in kidney patient care, and to help patients struggling to make ends meet. Both schemes are managed in a formal and consistent process, according to a clear and comprehensive set of guidelines. Hospital grant applications are formally peer reviewed by the Grants Committee, containing experts in their field, and scored against clearly defined and published guidelines. The Committee makes a recommendation for funding to the Board for their review and approval. In all instances where there is a conflict of interest, the Committee Member is excluded from any discussion and decision.
**----- Start of picture text -----**
67
**----- End of picture text -----**
## **Our structure, governance and management**
## **Structure**
Kidney Care UK is a charitable company limited by guarantee, incorporated on 29th September 1975. The company was established under a Memorandum of Association which establishes it objects and powers and is governed under its Articles of Association. The company is registered as a company in England and Wales, registration number 1228114. Kidney Care UK is registered as a charity with the Charity Commission for England and Wales, charity number 270288 and in Scotland with the Office of the Scottish Regulator, registration number SC048198. In the event of the company being wound up members are required to contribute £10.
## **Trustees**
The Board of Trustees is legally responsible for directing our affairs. They are Directors of the company and serve for renewable terms of three years, up to a maximum of nine years. Our articles mandate that the Board should be between 8 and 16 members and the Charity considers that 12 is the optimum number of Board members to service the Committees of the Board. As at the date of signing the Charity had a total of 14 Trustees. The Board have a wide range of skills, knowledge and experience including clinical and professional. We monitor the mix of skills and length of service to ensure that we maintain a good balance and recruit new Trustees in a timely fashion. The Trustees who served during the year are detailed on pages 73 to 74.
The Board appoints all new Trustees on the advice of a Nominations Committee, and we recruit Trustees through a process of advertisement, application and interviews, and on a selection criterion that ensures a broad range of relevant skills, experience and diversity is maintained. We offer a tailored induction programme and provide further updates and training as needed. The Board makeup is reviewed annually at Board level.
The Board of Kidney Care UK are committed to good governance and recognise the importance of continued development. Following a full external governance review in 2019, the Charity conducts an annual Board self-evaluation survey, which along with any changes to the Governance Code, results in an annual Board Governance Development Plan, ensuring a culture of ongoing review and improvement. Changes to the Charity Commission Governance Code, published in December 2020, were reviewed by the Governance, Strategy & Risk Committee in 2021 and actions as a result were reflected in the annual plan to ensure continued compliance both in letter and spirit.
**----- Start of picture text -----**
68
**----- End of picture text -----**
## **Decision making**
The Board of Trustees meets four times a year to regularly review Kidney Care UK’s general policies, strategy, budget and performance. The Board delegates the day-to-day management of the Charity to the Chief Executive and Senior Management Team. Specific responsibilities are delegated to four Board Committees, under terms of reference agreed by the Board and which report back to the Board on a regular basis. All Committees are advisory and decision-making authority is retained by the full Board.
- Audit and Risk Committee. This Committee is responsible for ensuring the Board fulfils its legal, ethical, and functional responsibilities through effective governance. This Committee reviews the effectiveness of the system of internal control, governance and risk management and the adequacy of external audit services liaising with the Finance and Investment Committee where required. The committee meets twice a year.
- Finance and Investment Committee. This Committee is responsible for ensuring the effective financial stewardship of the Charity and the management of the investment portfolio. This includes reviewing and ensuring our sustainable investment (ESG) approach is regularly considered and discussed at the Board. It makes recommendations to the Board on plans and budgets and monitors performance against these and reviews the Annual Report and Accounts. It recommends investment policy and oversees its effective implementation, ensuring compliance with regulatory requirements and Kidney Care UK’s governing document. The committee meets four times a year.
- Grants Committee. The Grants Committee meets up to twice a year and receives and considers all applications for grants of more than £10,000 from NHS Trusts and other organisations, such as local kidney patient associations and the UK Renal Registry. It advises the Board on which grants should be approved. The Committee also regularly reviews Kidney Care UK’s grant making policies. It is currently the only committee which includes lay members.
- Staffing and Remuneration Committee. The Committee is responsible for supporting the Board in determining the remuneration and terms and conditions of the Chief Executive, other SMT members and employees of the Charity, and for overseeing the development and implementation of suitable human resources policies and procedures. The committee meets twice a year.
## **Key management and staff remuneration**
The Senior Management Team is responsible for the day-to-day running of the Charity and comprises the Chief Executive, and the Directors of Policy, Fundraising, Marketing & Communications, Finance, and Patient Support.
**----- Start of picture text -----**
69
**----- End of picture text -----**
The pay of the Charity’s Chief Executive is reviewed annually by the Board, based on market rates and benchmarks, personal performance and scope and complexity of the role.
## **Volunteers**
The Board and Senior Management Team are supported and advised on issues affecting patients by our Patient Advisory Group (PAG), made up of around 20 kidney patients and carers, many of whom are officers of local kidney patient associations. In addition, the Charity recruits peer supporter volunteers to deliver its peer support service, who are managed by the Peer Support and Volunteer Manager. As with Trustees, volunteers receive no remuneration, only expenses.
## **Our risk management**
The Board of Trustees has overall responsibility for risk management at Kidney Care UK. This includes setting the risk appetite for the Charity (formal risk appetites are codified in the Charity’s risk register), ensuring that there are reasonable procedures in place for the prevention and detection of major risks and ensuring that risk procedures are reviewed when issues arise. The Board formally review the Risk Policy and Register twice a year. The Board considers risks to be anything that can adversely affect our ability to achieve our objectives for people affected by kidney disease, sustain our operations, maintain our reputation or meet legal and regulatory requirements. The Charity maintains a suite of core organisational policies, covering all aspects of its work and management, which are subject to a formal, regular review cycle and supported by our committee structure.
The Board are supported by the Audit and Risk Committee (A&R) which plays a key role in overseeing management of our principal risks and provide assurance to the Board that we have adequate risk management systems and mitigating actions in place. The Committee undertakes twice yearly risk reviews and the Senior Management Team monthly meetings, chaired by the Chief Executive, oversee a comprehensive annual planning and budgeting process, performance monitoring through key performance indicators and a regular review and monitor of key strategic and operational risks. The Board consider this an effective approach to evaluate significant risks to the Charity, establish effective controls and determine necessary and prompt action.
**----- Start of picture text -----**
70
**----- End of picture text -----**
## **Principal risks identified and controls**
## **Data and information security**
We have a dedicated Data and IT Manager who ensures that policies and procedures are in place to protect staff, supporter and beneficiaries’ personal data, oversee regular (annual) staff training on data protection and cyber security, and ensure we comply with the highest standards stipulated in guidelines and regulations. The Charity regularly reviews its data protection and privacy policies and conducts security audits with independent third-party organisations to ensure its cyber security is robust. In 2024, as a result of the increased threat from cyber-attacks we conduct annual penetration testing to ensure that our security systems and protocols were sufficient and were pleased that only low risks were identified. In 2024 we were also pleased to retain our Cyber Essentials accreditation and we continue to ensure we maintain the Charity’s high levels of security.
## **Service quality in patient care**
Kidney Care UK’s key risk is that patients receiving support from the Charity suffer harm or ineffective care as a result of our actions. The Charity has a robust safeguarding policy, including a Designated Safeguarding Officer and Deputy Safeguarding Officer, the Patient Services Team meets quarterly and receives regular high-quality training on areas such as safeguarding and Equality and Diversity, and the Charity has a published complaints policy and log, which is regularly reviewed by the SMT and the Board, along with patient and carer feedback and incident reporting. Our counselling service is staffed by fully qualified and accredited counsellors who adhere to the BACP guidelines and regulatory framework. We continue to strengthen our Safeguarding governance framework and have a named Trustee to act as the Board Safeguarding Lead.
## **Investment performance**
Kidney Care UK’s investments are managed on a total return basis. The Trustees consider variability of returns on the Charity’s investment portfolio and a significant drop in the value of the portfolio to constitute the Charity’s principal financial risk. A 10% drop in the value of the portfolio triggers the discretionary investment managers and the finance advisors to enter immediate discussions with the Finance and Investment Committee. Investment managers and our financial advisors produce regular reports (quarterly) to the Finance and Investment Committee, which in turn reports quarterly to the Board of Trustees. The investment portfolio is divided between two investment managers to reduce the Charity’s investment risk profile, and the Board have agreed a medium risk appetite. In 2022, the Trustees agreed to strengthen our alignment with ESG investment principles, but through a progressive approach
**----- Start of picture text -----**
71
**----- End of picture text -----**
that does not alter the primary objective of protecting and responsible management of the Charity’s current capital assets. The Finance and Investment Committee are charged with taking this programme of work forward.
## **Fundraised income**
Kidney Care UK’s strategic growth is dependent on achieving fundraising targets. The organisation has developed a fundraising strategy that looks to realise a diverse range of funding opportunities and a mature, balanced fundraising programme. We have strengthened the knowledge and skills in the fundraising team to enable delivery of our strategy. Monitoring of actual income to budget and forecast is achieved by a monthly review of reports by senior management and with oversight by the Finance and Investment Committee. Kidney Care UK regularly reviews its fundraising procedures to ensure compliance with the Fundraising Code of Practice. There were no identified failures in compliance with this Code, nor any complaints received by the Charity in respect of fundraising in the year. Kidney Care UK protects vulnerable people and other members of the public by ensuring that its fundraising activities are not considered to be an unreasonable intrusion on a person’s privacy or an unreasonably persistent approach and do not place undue pressure on a person to give money.
## **Loss of key staff**
In common with most small and medium sized charities, Kidney Care UK is at risk of performance challenges through the loss of key staff. The Charity’s transformation in recent years has allowed us to reduce this risk by developing greater sustainability through increasing staffing for key roles. Having strengthened the Senior Management Team in 2022, we have continued (funds permitting) to increase staff numbers in areas where the pressure of increasing work volumes and threat of “single points of failure” or lack of segregation of duties, increase our risks. We introduced our first Staff Engagement Survey in 2023 and were pleased to achieve an 82% Staff Engagement Index score, we undertook this survey in 2024 and were delighted to achieve an 85% Staff Engagement Index Score as well as reviewing our staff benefits package and launching an enhanced package in January 2024.
**----- Start of picture text -----**
72
**----- End of picture text -----**
## **Reference and administrative details of the Charity, its Trustees and advisors**
## **Trustees**
Graham Lipkin MB ChB, BSc, MD, FRCP (UK) (Chair) Amar Radia ACA, MA (Cantab) Angela Griffiths (Chair of Staffing and Remuneration Committee) Caroline Price Grainne Walsh MSc, BSc, DipHe(Nurs), RSCN (Chair of Grants Committee) John Henry Brown MD, FRCP, FRCPI Lewis Temple Madeleine Warren Michael Zelouf Robert Lant (Chair of Finance and Investment Committee) Sally Hulton MD, FRCPCH, MBBCh Sarah Hillary (Chair of Audit and Risk Committee) Shivani Sharma CPsychol William Richard Caldwell
## **Company Registered Number**
1228114 (England and Wales)
## **Charity Registered Number**
270288 (England and Wales) SC048198 (Scotland)
## **Registered Office and Operating Office**
3 The Windmills, St Mary’s Close, Turk Street, Alton, Hampshire, GU34 1EF
## **Chief Executive**
Paul Bristow
**----- Start of picture text -----**
73
**----- End of picture text -----**
## **Senior Management Team**
Paul Bristow
Fiona Loud
Laurie Cuthbert Sarah Oakley Charlotte Donnelly
## **Company Secretary**
Southern Secretarial Services Ltd, Wey Court West, Union Road, Farnham, Surrey, GU9 7PT
## **Auditors**
Kreston Reeves, 9 Donnington Park, 85 Birdham Road, Chichester, PO29 7AJ
## **Bankers**
Lloyds TSB PLC, 75 Castle Street, Farnham, Surrey, GU9 7LT
## **Investment Managers**
Cazenove Capital Management, 12 Moorgate, London EC2R 6DA CCLA Investment Management Limited, One Angel Lane, London, EC4R 3AB
## **Investment Advisers**
Enhance Group Limited, 3rd Floor, 29/31 Esplanade, St Helier, Jersey JE2 3QA
**----- Start of picture text -----**
74
**----- End of picture text -----**
## **Statement of Trustees’ responsibilities For the year ended 31 December 2024**
The Trustees (who are also the directors of the Charity for the purposes of company law) are responsible for preparing the Trustees’ report including the Strategic report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).
Company law requires the Trustees to prepare financial statements for each financial year. Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:
- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in business.
The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity’s transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
## **Disclosure of information to auditors**
Each of the persons who are Trustees at the time when this Trustees’ report is approved has confirmed that so far as that Trustee is aware, there is no relevant audit information of which the Charity’s auditors are unaware, and that Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any relevant audit information and to establish that the Charity’s auditors are aware of that information.
In approving the Trustees’ Annual Report, we also approve the Strategic Report included therein, in our capacity as Company Directors.
**----- Start of picture text -----**
75
**----- End of picture text -----**
Approved and authorised for issue by the Trustees and signed on their behalf by:
................................................
## **Dr Graham Lipkin MB ChB, BSc, MD, FRCP (UK)**
Chair of Trustees Date: 25 June 2025
**----- Start of picture text -----**
76
**----- End of picture text -----**
## **Auditors’ report**
## **THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK**
(A company limited by guarantee)
## **INDEPENDENT AUDITORS’ REPORT TO THE MEMBERS OF THE BRITISH KIDNEY PATIENT ASSOCIATION T/A KIDNEY CARE UK**
## **Opinion**
We have audited the financial statements of The British Kidney Patient Association t/a Kidney Care UK (the ‘Charity’) for the year ended 31 December 2024 which comprise the Statement of financial activities, the Balance sheet, the Statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland’ (United Kingdom Generally Accepted Accounting Practice).
In our opinion the financial statements:
- give a true and fair view of the state of the charitable company’s affairs as at 31 December 2024 and of its incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland} Act 2005 and regulation 8 of the Charities Accounts (Scotland} Regulations 2006.
## **Basis for opinion**
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors’ responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council’s Et ical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
**----- Start of picture text -----**
77
**----- End of picture text -----**
## **Conclusions relating to going concern**
In auditing the financial statements, we have concluded that the Trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.
## **Other information**
The other information comprises the information included in the Annual report other than the financial statements and our Auditors’ report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
## **Opinion on other matters prescribed by the Companies Act 2006**
In our opinion, based on the work undertaken in the course of the audit:
• the information given in the Trustees’ report including the Strategic report for the financial year for which the financial statements are prepared is consistent with the financial statements.
• the Trustees’ report and the Strategic report have been prepared in accordance with applicable legal requirements.
**----- Start of picture text -----**
78
**----- End of picture text -----**
## **Matters on which we are required to report by exception**
In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees’ report including the Strategic report.
We have nothing to report in respect of the following matters in relation to which Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:
- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees’ remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.
## **Responsibilities of Trustees**
As explained more fully in the Trustees’ responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.
In preparing the financial statements, the Trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.
## **Auditors’ responsibilities for the audit of the financial statements**
We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Act and relevant regulations made or having effect thereunder.
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors’ report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it
**----- Start of picture text -----**
79
**----- End of picture text -----**
exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:
## **Capability of the audit in detecting irregularities, including fraud**
The objectives of our audit are to identify and assess the risks of material misstatement of the financial statements due to fraud or error; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud or error; and to respond appropriately to those risks.
Based on our understanding of the Charity and industry, and through discussion with the directors and other management (as required by auditing standards), we identified that the principal risks of noncompliance with laws and regulations related to health and safety, anti-bribery and employment law. We considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the preparation of the financial statements such as the Companies Act 2006, Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland. We communicated identified laws and regulations throughout our team and remained alert to any indications of non-compliance throughout the audit. We evaluated management’s incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to: posting inappropriate journal entries to increase income or reduce expenditure, management bias in accounting estimates and judgemental areas of the financial statements such as accounting treatment of grants awarded not yet claimed and accounting for legacies receivable. Audit procedures performed by the engagement team included:
- Discussions with management and assessment of known or suspected instances of non-compliance with laws and regulations (including health and safety) and fraud; and
- Assessment of identified fraud risk factors; and
- Challenging assumptions and judgments made by management in its significant accounting estimates; and
- Performing analytical procedures to identify and unusual or unexpected relationships, including related party transactions, that may indicate risks of material misstatement due to fraud; and
**----- Start of picture text -----**
80
**----- End of picture text -----**
- Confirmation of related parties with management, and review of transactions throughout the period to identify any previously undisclosed transactions with related parties outside the normal course of
- business; and
- Reading minutes of meetings of those charged with governance; and
- Review of significant and unusual transactions and evaluation of the underlying financial rational supporting the transactions; and
- Identifying and testing journal entries, in particular any manual entries made at the year end for financial statement preparation; and
- Performing substantive procedures on grant approvals at board level, progress of conditions being met and identification of grants not recognised that may indicate risks of material misstatement due to fraud; and
- Confirmation of legacy estimations susceptible to fraud or irregularity from solicitors.
Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.
As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion of the effectiveness of the charitable company’s internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Trustees.
- Conclude on the appropriateness of the Trustees’ use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention
**----- Start of picture text -----**
81
**----- End of picture text -----**
in our Auditors’ report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditors’ report. However, future events or conditions may cause the charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
## **Use of our report**
This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company’s trustees, as a body, in accordance with regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company’s members and Trustees those matters we are required to state to them in an Auditors’ report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.
................................................
## **Lucy Hammond BSc FCA (Senior Statutory Auditor)**
for and on behalf of
## **Kreston Reeves LLP**
Chartered Accountants Chichester
Date: 7 July 2025
**----- Start of picture text -----**
82
**----- End of picture text -----**
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
{A company limited by guarantee)
STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUND
FOR THE YEAR ENDED 31 DECEMBER 2024
Endowment
funds
2024
Restricted Unrestricted
funds
funds
2024
2024
Total
funds
2024
Total
funds
2023
Note
Income and
endobvments frorn:
Donations and legacies
Charitable activities
Other trading aclivits'es
Investments
468.282
941,285
1.891,689
2,359.981
941,285
47,954
772,780
2,107,610
178,157
55,122
711,313
47,4
770,074
1,556
2,706
Other income
Total Income and
endo%Mnents
2,706
1,409,567
2,711,283
4,123,556
3,052,202
Expenditure on:
Raising funds
Chantable activities
9,10
11
72
3,113
1,391,243
1,045,702
4,270,825
1,048,887
5,664.702
925,994
4,503,936
2,634
Total expendlture
2,706
1,394,356
5,316,527
6,713,589
5,429,930
Net incorne I
lexpenditurel beforé
net Ilosse51 I gains
on inve5tment5
15,211
{2,8OS,2441 {2,$9),033) 12,377,728)
Nel Ilossesl I gains on
investments
5.606
2,138,853
2,144.369
1,211,629
Net income I
lexpenditurel
Transfers tEtween
funds
5,506
15,211
{466,3911
1445,674) 11,166,099)
24
123,1981
23,198
Net movement in
funds
5,506
17,9871
1443,1931
1445,674) 11,166.0991
Reconciliation of
funds..
Total funds brought
forward
.187
5,506
305,303
17,9871
27,131,956
{443,1931
27,527,446
28,693,545
1445,674) 11,166,099)
Nel movement In fuThJs
Total funds earrléd
forward
95,693
297,316
26,688,763
27,081,772
21,527,446
The Statement of financial activities includes all gains and losses recognised In the year.
The notes on pages 87tr) 113 form part of trese financial statements.
83
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
(A company limited by guarantee)
REGISTERED NUMBER.. 1228114
BALANCE SHEEr
AS AT 31 DECEMBER 2W24
2024
2023
Note
Fixed assets
IntangitAe assets
Tangible assets
IeStMentS
18
72,252
4,834
26,391,767
19
20
404,698
27,020,576
26,864,853
27,425,274
Current assets
Debtors
Cash at bank and in hand
21
1,252,842
426,447
563,845
618,754
1.679.289
1,182,599
Creditors.. amounts falling due within one
year
22
11,317,031)
1933,8411
Net current assets
362,258
248,758
Total assets less current liabilities
27,227,111
27,674,032
Creditors.. amounts falling due after more
than one year
23
114S,3391
1146,5861
Total net assets
27,081,772
27,527,446
84
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
{A company lirnited by guarantee)
REGISTERED NUMBER.. 1228114
BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2W24
2024
2023
Note
Charity funds
Endowrnenl furKJs
24
95,693
297,316
26,688,763
90,187
305,303
27,131,956
Restricted funds
Unrestricted funds
24
24
Total funds
27,081,772
27,527,446
The Trustees acknoedge their resKx)nsibilities for complying wrth the requirements of the Act with respect lo
8ccounting records arKI preparation of finawial statements.
The financial staterrEnls were approved and autkKJrised for issue by the Trustees and signed on their Ikhalf ty".
Mr Robert Lant
Chair of Finance and Investment Committee
Dale.. 25 June 2025
The notes on pages 87 to 113 form part of these financial statements.
8S
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
(A company Ilmlted by guarantee)
STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2W24
2024
2023
Cash flows from operating activities
Net cash used In oper8ting adwities
{3,630.7001 12,542,156)
Cash flows from investing activities
8ank interest
Dividend Income
1,181
703,891
771,790
1,556
(109,1111
150,3151
18,531310
7,147,631
115,471,873) 15,499,154)
Proceeds from the sale of laryible fixed assets
Purchase of fixed assets
Net proceeds from sale of InvestrrEnts
Purchase of investments
Net cash provided by investing activities
3,725,662
2,303,234
Change in cash and cash equivalents in the year
84.962
(238.922)
Cash and cash equivalents al the teginning of the year
1,083,425
1,322,347
Cash and cash equivalents at the end of the year
1,178,387
1.083,425
The notes on pages 87 to 113 form part of these fina[la1 statements
86
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
(A company lirnited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
General information
The company is a charitable o)mpany limited ty guarantee, incorwraled in England and Wales. The
Iruslees on page 1 are also members of the company. In the event of the company being wound up, the
liability in respect of the guarantee is limited lo £10 per memter.
The registered office is 3 The WirKJmills, Sl Mary's Close, Turk Street, Alton, GU34 1 EF.
Accounting policies
2.1 Basis of preparation of financial statements
The financial statements have tEen prepared In accordance with the Charities SORP IFRS 1021
Accounliry and Reporting ty Charities Statement of Recommended Practice applicable lo charities
preparing their accounts in accordance with the Financial Rew>rting Stsndard applicable in the UK
and Republic of Ireland IFRS 1021 (effective 1 January 20191, the Financial ReEK)rting Standard
applicable in the UK arKJ RepubliG of Ireland IFRS 1021 and the Companies AGt 2006.
The British Kidney Patient Association Ve Kidney Care UK meets the definition of a public benefit
entity under FRS 102. Assets and liabilities are Initially recognised al historical cost or transaction
value unless otrewise stated in the relevant accounting Kx)IIGy.
2.2 Going concern
The Trustees have a reasonable exFeclation that the charity has adequate resources to continue in
operational existence for the foresee8ble future. Thus they continue to adopt the going concern basis
in preparing the annual financial stalemenls. The continuing Impact of the cost of living crisis has
teen included in charity's forecasting and in the planning of future and the going conrn
assumption takes this into consideration.
2.3 Income
All income is reGognised onGe the Charity has enlrtlement lo the Income, it is probable th8t the
income will LE reTrived and tre amount of iwome receivable can be rrEasured reliably
The reGognition of Income from legacies is dependent on establishing enb"tlement, the probability of
receipt and the 3bility to estimate witr sufficient accuracy the amount re1Vable. Evidence of
enlillement to a legacy exists when the Charity has sufficient evidence th8t a gift has been lefl lo
them (through knowledge of the eXiStee of a valid will and the death of the tEnefactorl and the
executor Is s8tisfied that the propetty in question will not LE required to S8tisfy claims In the estate.
Receipt of a legacy must recogni*d when It is prothable that il will received and the fair value
of the amount receivable, which will nerallY te tre expected cash amount to tE distritrArted lo the
Charty, can be reliably measured.
Grants are Included In the Statement of financial activities on a receivable basis. The balance of
income received for specific purposes t not exFended during the period is skx)wn In the relevant
funds on the Balance sheet. Where Income Is received in advan of entitlement of reipt, its
recognition is deferred and Included in creditors as deferred Iwome. Where entitlement occurs
tefore income Is received, the Imome is accrued.
Income lax recoveratAe in relation lo investment income is reccNJnised at the lime the investment
income is receivable.
87
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
(A cornpany limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 21r24
Accounting policies Icontinuedl
2.4 Expenditure
Expenditure is recognised once there is a legal or constructive otAigation to transfer economic tenefit
lo a third paty, it is probable that a transfer of economic nefItS will be required in selllemenl and
the amount of the obligation can rrÈasured reliably. Expenditure is classified by activity. The costs
of each activity are made up of the total of direct costs and shared costs, including support costs
involved in undertaking each activity. Direct costs attriblrtable lo a single activity are allocated directly
to that activity. Shared costs which contribute to more than one activity and support costs which are
not allributable to a single activity are apportioned t£een those activities on a basis consislenl with
the use of resources. Central staff costs are allocated on the basis of time snt, and depreciation
charges allocated on the portion of the asset's we.
Expenditure on raising funds includes all expenditure incurred by the Charity lo raise funds for its
charitable purwses and includes costs of all fundraising activities events and non-charilable trading
Expenditure on charitable activities is incurred on directly undertaking the acb'vilies which further the
Charity's objectives, as well as any associated support $ts
Grants payable are charged in the year when the offer is made except in those cases where the offer
is conditional, such grants being recognised as expenditure when the conditions attaching are
fulfilled Grants offered subject lo conditions which have not tEen rnel at the year erKJ are noted as a
commitment, but not accrued as exFEndilure
2.5 Interest receivable
Interest on funds held on dewsit is included when receivable and the amount can LE rnea5ured
reliably by the Charity, this Is norrnally notification of the interest paid or payable by the
inslilubon with whom the funds are desIted
2.6 Takition
The Charity is considered to pass the lesls set out in Paragraph 1 Schedule 6 of the FIrnan Act
2010 and therefore Il meets the definition of a charitable company for UK corporation tax purrx)ses.
Accordingly. the Charity is FK)tentially exempt from taxation In respect of income or capital gains
reIVed within categories covered by Chapter 3 Part 11 of the CorFX)ralion Tax Act 2010 or Section
256 of the Taxation of Chargeable Gains Art 1992, to the extent that such income or gains are
applied exclusively to charitable purtx)ses.
2.7 Intangible assets and amortisation
Intangible assets Gosting £1,000 or more 8re caprtalised and recognised when future economic
Ine[lIS are probable, 8nd the cost or value of tre asset can LE measured reliably.
Intangible assets 8re Inrtially recognised al cost. After recognition, urKler the cost model, intaruible
8ssels are measured al cost less any accumulated amortisalion and any accumulated Impairment
losses.
Amortisalion is provided on intangible assets at rates calculated to write off the cost of each asset on
a straight-line basis over its exFecled useful life.
estimated useful lives are as follows..
Computer sofvare
8 years
88
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
(A company lirnited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
Accounting policies (continued)
28 Tangible fixed assets and depreciation
Tangible fixed assets costing £1,000 or more are capitalised and reccNJnised when future economic
tenefits are probatAe and the cost or value of the asset can measured reliably.
Tangible fixed assets are initially recognised al cost. After recognition, urKler the cost m(e1, tangible
fixed assets are measured al st less accumulated depreciation and any accumulated impairrrEnt
losses. All costs incurred to bring a tangible fixed asset into ils intended working condition should
induded in the measurement of cost.
[preCIatIon is charged so as lo allocate the cost of tangible fixed assets less IkEir residual value
over their eslimaled useful lives, using the straight-line melkK)d.
[preCIatIon is provided on the following bases..
Freehold proFerty
Fixtures and fittings
Office equipment
50 years straight line
10 years slraighl line
3 years straight line
29 Investments
Fixed asset investments are a form of financial instrument and are initially recognised at their
transaction cost and subsequently measured at fair value al the Balance sheet dale, unless the value
cannot be measured reliably in which case il is measured at cost less impairment Investment gair
and losses, whether realised or unrealised, are combined and presented as 'GainsllLossesl on
investwÈnts' in the Statement of financial activities.
210 Debtors
Trade and other debtors are recognised at the settlement amoLJnt after any trade discount offered.
Prepayments are valued al the amount prepaid net of any trade discounts due.
211 Cash at bank and In hand
Cash at bank and in hand inclLJdes cash and short-term highly liquid investments with a short maturity
of three months or less from the date of a(4LJiSition or 0[nIng of the deposit or similar account.
89
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
(A cornpany limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
Accounting policies (continued)
2.12 Liabilities and provisions
Liabilities are recognised when there is an obligation al the Balance sheet dale as a result of a past
event, il is probable that a transfer of economic tenefit will tE required in settlement, and the amount
of selllement can tE estimated reliably.
Liabilities are recognised al the amount tral the Charty anticipates il will pay lo sellle the debt or tk
amount it has received as advanced payments for the goods or *rvices it musl provide.
A conlingenl liability is identified and disclosed for those grants resulting from..
a wssible obligation which will only be confirmed ty the occurrence of one or more uncertain
future events not wholly within the Iruslees, control.. or
a present obligation followir¥J a grant offer where settlerrEnt is either not considered probable,
or
the amount has not teen communicated In the grant offer and that amount cannot te
estimated reliauy.
2.13 Flnanclal Instruments
The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial
instruments Basic financial instruments are inrtially recognised al transaction value and SLJbseqLJently
measured al their settlement valLJe with the exception of bank loarts which are SLJbsequendy
measured at amrtised c051 u&ng the effective interest metthd.
2.14 Pensions
The Charity OFErates a defined contritxrtion pension scheme and the nSIOn charge represents t
amounts payable ty the Charity lo the fund in respect of the year
2.15 Fund accounting
General funds are unrestricted funds which are availatAe for use al the discretion of the Trustees in
furtherance of the general objectives of the Charity and which have not been designated for other
purposes
Designated funds cornprise unrestricted funds that have been set aside by the Trustees for pgrticular
purposes The aim and use of each designated furKJ is set out in the note5 to the financial
statements.
Restricted funds are furKJs which are lo tE used in accordance with specific reslriclions irnposed by
dorK)rs or which have raised by the Chanty for particular purSes. The costs of raising and
administering such funds are charged against the specific fund. The aim and use of each restricted
fund is set out in the notes lo the financial statements.
Endowment funds are funds, the incorrE from which, are to Used In accordance with spEcific
reslriclions IrnFK>sed by donors The cost of raising and administrating such funds are charged
against the SFEcific fund. The aim and use of the endowment fund is sel out In the notes to the
financial statements
Investment Income, gains and losses are allocated to the appropriate fund.
90
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
IA company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
Critical accounting estimates and areas of judgment
Estimates arKJ judgments are continually evaluated and are based on historical experieme and other
factors, including expectations of future events that are tElieved lo be reasonatAe under the
circumstances.
Critical accounting eslimales and assumptions..
The Charity makes estimates and assumptions concerning the future. The resulting accounting ests'mates
and assumptions will, by definition, seldom equal the related actual results. The estimates and
assumptions that have a significant risk of causing a material adjustment to the carrying amounts of
assets aThJ lialj'lrties within the next financial year are discussed tlow.
Critical areas of judgment..
Le
cies receivable
The Charity only recognises legacy income when il is certain to be received and can measured or
estimated with sufficient reliability Estimations of legacy income may based on a solicitor5 valuation of
an estate and therefore adjustments may need lo be made following actual receiF*s. Therefore some
amounts included in the financial stalernents are estirnations.
Grants comrnitted
The Charity recognises grants committed as a contingent liability once the grant has been approved by the
Grants Committee When the conditions of the grant are achieved by all parties, the grant Is recognised
as a creditor in the financial statements A ILKJgement is made to determine that all conditions have tEen
satisfied.
91
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
IA company Ilnlted by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
Income from donations and legacies
Restricted Unrestricted
funds
funds
2024
2024
Total
funds
2024
Donati0Tr6
Legacies
Grants
397,570
70,712
1,176,191
698,908
16,600
1,S73,761
769,620
16,600
Total 224
468,282
1,891,699
2,359,981
Restricted Unrestricted
funds
funds
2023
2023
Total
funds
2023
Donations
383,627
1,244,878
479,105
1,628,505
479,105
Legacies
Total 2023
383,627
1,123,983
2,101,610
Income from charitable activities
Restricted
funds
2024
Tolal
funds
2024
Direct patient support
941,285
941,285
Restricted
funds
2023
Total
funds
2023
Direct patient support
178,157
178,157
92
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
IA cornpany limitad by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
Income from other trading activities
Income from non charitable trading activities
Unrestricted
funds
2024
Total
funds
2024
Non-charitable trading - MercharKlise sales
47,954
47,9S4
Unreslricled
funds
2023
Total
funds
2023
Non-charitable trading - MercharKlise sales
55,122
55,122
Investment income
Endowment Unrestricted
funds
funds
2024
2024
Totsl
funds
2024
Income frorn listed investrnents
2,706
769,084
990
771,790
Bank interest
Total 2024
2,706
770,074
772,780
Endowment Unrestricted
funds
funds
2023
2023
Total
funds
2023
IncorrE from listed IestmentS
Bank interest
2,102
708,030
1,181
710,132
1,181
Total 2023
2,102
709,211
711,313
93
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
IA company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
other incoming resources
Unrestricted
funds
2024
Total
funds
2024
Total
funds
2023
Other iwome
1,556
1,SS6
Investment management costs
Endowment Unrestricted
funds
funds
2024
2024
Total
funds
2024
Investment management fees
72
121,503
ErKJowmenl Unreslricled
funds
funds
2023
2023
Total
funds
2023
Investment management fees
72
156,743
156,815
10. Expenditure on raising funds
Costs of raising voluntary income
Restricted Unrestricted
funds
funds
2024
2024
Total
funds
2024
Costs of raising voluntary income
3,113
924,271
927,384
94
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
IA company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
10. Expenditure on raising funds {continued)
Costs of raising voluntary income Icontinuedl
Unreslricled
funds
2023
Total
funds
2023
Costs of raising voluntary income
769,179
769,179
11.
Analysis of expenditure on charitable activitiés
Surnmary by fund type
EndOwnnt
funds
2024
Restricted Unrestricted
funds
funds
2024
2024
Total
2024
Direct patient support
2,634
1,391,243
4,270,825
5,664.702
Endowment
funds
2023
Restricted Unreslricled
funds
funds
2023
2023
Total
2023
Direct patient support
2,030
410,095
4,091,811
4,503,936
12.
Analysis of expenditure by activities
Activities
undèrtaken
directly
2024
Grant
funding of
artivities
2024
Support
costs
2024
Total
funds
2024
Direct patient support
2,889,345
1,460,416
1,314,941
5,664,702
9S
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
IA company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
12. Analysis of expenditure by activities (continued)
Activities
urdertaken
directly
2023
Grant
funding of
activities
2023
SupFK)rt
costs
2023
Total
funds
2023
Direct patient support
2,085,098
1,244,391
1,174,447
4,503,936
Analysis of direct costs
Direct
patient
support
2024
Total
funds
2024
Counselling
Advocacy
Influencing Policy
Patient information
Other direct SUPFK)rt
157,530
1,376,287
228,250
775,984
351,294
157,530
1,376,287
228,250
77S.984
351,294
Total 2024
2,889,345
2,889,345
Direct patient
suptK>rt
2023
Total
fLJnds
2023
Counselling
Advocacy
Influemiry Policy
Patient information
193,975
916,214
235,517
645,778
93,614
193,975
916,214
235,517
6,778
93,614
Other direct SUPKK>rt
Total 2023
2,085,098
2,085,098
Staff c051s comprising wages and salaries, social security costs and wnsion costs are allocated across
the different services provided.
96
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2W24
12. Analysis of expenditure by activities {continued)
Analysis of support costs
Direct
patient
support
2024
Total
funds
2024
Governan
Finance
193,223
157,757
205,426
170,436
180,738
277,463
129,898
193,223
157,757
20S.426
170,436
1,738
27T,463
129.898
Information Technology
Human Resources
Premises and Facilib'es
Cornmunications
Grant staff and administration costs
Total 2tr24
1,314,941
1,314,941
Direct patient
supwrt
2023
Total
funds
2023
Governan
Finance
171,095
137,965
185,162
139,416
173,699
236,371
130,739
171,095
137,965
185,162
139,416
173,699
236,371
130,739
Information Technolog
Human Resources
Premises and Facilib'es
Communications
Grant staff and administration costs
Total 2023
1,174,447
1,174,447
Staff costs comprising wages and salaries, social secLJrity costs and tension costs are allocated across
the different services provided
13. Analysls of grant funding actlvities
Grants to
Grant5 to
Institutions Individuals
2024
2024
Totsl
funds
2024
Grants- patient supwrt
542,795
917,621
1.460,416
97
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
13. Analysis of grant funding activities Icontinuedl
Grants to
Institutions
2023
Grants to
Individuals
2023
Total
funds
2023
Grants- pats'ent supwrt
438,226
806,165
1,244,391
Grants bytype
2024
2023
Post funding, projects and equipment
Dialysis freedom
Small grants
Grants to patients
Research]Development
Mount Cook
385.553
48,496
9,232
917,621
58.025
41,489
302,318
48,420
14,200
806,165
39,688
33,600
Totsl grants
1,4,416
1,244,391
98
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
2024
2023
Grants by Instltutlon
Alder Hey Children's Hospital
Belfast City Hospital
British Psy¢hologic81 Society Renal Psychologists SpEoi31 Interest Group
Bristol Royal Hospitsl for Children
Dialysis Freedom
Evelina Children's Hospital
Great Ormond Street Hospital for Children
Guls Hospital
Leeds Children's Hospital
Leeds General Infirmary
Leeds Teaching Hospital
Leicester GerEral Hospitsl
Manchester Childrerfs Hospital
Manchester Royal Infirmary
Mount Cook
Newcastle, Freernan Hosytal
Nottingham Children's Hospitsl
Nottingh3m University Hosptal NHS Trust
other grants, including small grants
PNNG Paediatric Nephrology Group
Queen Alexandra Hospital - Wessex Kidney Cent
Qun E11281Elh Birmingham
Qu*n's Medical Centre, Nollir¥Jham
Queen's University Hospital Belfast
Renal Psychological Therapists
Renal Social Workers
Royal Belfast Hospital for Sick Children
Royal Manchester Children's Hospital
Shrewsbury and TeOrd Hospital NHS Trust
Southampton Children's Hospital
Southend Hospital - Mid and South Essex Foundation Trust
South East Scotland Kidney Pab'ent Association
The 8ntish Dietetic Association
4,C0
1,140
4,(M)O
1,500
2,500
48,420
3,(K)O
3,(K)O
2,162
7,212
48,496
3,0
3.WO
1,256
5,500
2.lJ)O
4,tK)O
3,(X)O
2,0
4,0
2.lJ)O
41,489
2,0
11,710
2.IXIO
70,214
33,600
2,(M)O
3,(X)O
75,088
2,500
1,$00
1.350
10,350
54,814
4,tK)O
4.¢X)O
9.WO
5,000
4,596
4,1X)O
10.754
5,WO
107,(M)2
48,0
4,(X)O
The Renal Association
University Hospital of Wales
University Hospital Southampton
University of Dert¥
York & Scartorough Teaching Hospital
Young Adult Kidney Group AGI
Lapsed or cawelled grants for prior years
310,677
2,231
3,(K)O
14,534
75,(M)O
1,IX)O
136,0711
(61.503)
Total grants to institutions
S42.795
438,226
99
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
{A cornpany limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
14. Taxation
The Association is a charity and Is entitled to exemption from taxation on rts charit8ble Income 8nd profits
virtue of Section 505 of the IncorrE and CorForalion Taxes Act 1988.
15. Auditors. remuneration
The auditors. remuneration amounts lo an auditor f of £18,650 Q023 £16,600), and statutory
accounts preparation of £2,65012023 - ,5001.
16. Staff costs
2024
2023
Wages and salaries
Social security costs
Pension costs
2.813.306
260.109
221,695
2,058,627
196,691
139,019
3,295,110
2,394,337
The average number of persons employed by the Charity during the year was as follows..
2024
No.
2023
No.
Grants and Fatient aid linduding support costs)
Fundraising
Advocacy Service
Counselling service
Policy seNice
Management and administration
10
13
38
10
12
22
21
19
91
71
The number of employees whose employee benefits lexclLhJing employer Fension costs) exeded
£60,000 was..
2024
2023
£60k- £70k
£70k- £80k
£80k- £gOk
£100k-£110k
The key m8nagemenl personnel of the charity comprise the trustees, the Chief Executive Officer, Policy
Director, Director of Marketing aThJ Communications, Finance Director and Director of Patient Supwrt
SeNices. The total employee berEfils of the key management Fersonnel of the charity were £426,412
12023. £390,774) and employer Fension contributions £34,28612023. £25,546).
100
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
17.
Trustees. remuneration and expenses
During the year, no Trustees received any remuneration or other benefils12023 - £NILI.
During the year ended 31 DecemtEr 2024, travel exFEnses lotslling £1,024 were reimbursed or paid
directly lo 3 Truslees12023 - £2,730 10 3 Trustees).
There is a total of £2,78812023'. £2,429) paid by the charity in relation to trustee indemnity insurance on
half of trustees.
18. Intangible assets
Computer
software
Cost
Additiorts
At 31 December 2024
72,273
Amortisation
Charge for the year
21
At 31 December 2024
21
Net l)ook value
Al 31 December 2024
72,2S2
At 31 December 2023
101
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
IA company lirnited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
19. Tangible fixed assets
Freehold Flxtures and
property
fittings
Office
uipment
Total
Cost or valuation
At 1 January 2024
Additions
Diswsals
395,595
105,132
164
127,859
.674
119,1371
828,588
36,838
{19,13n
At 31 December 2024
3,595
105,296
145,396
646,287
Depreciation
At 1 January 2024
Charge for the year
On disp)sals
74,648
4.419
S9,9)0
7.683
89,340
27.610
118,1471
223,888
39,712
{18,14n
At 31 December 2024
79,067
67,583
98,803
245,453
Net l)ook value
Al 31 December 2024
316,528
37,713
$93
400,834
At 31 December 2023
320,947
45,232
38,519
404,698
The Charivs premises were acquired in 2011. The larKI value was £100,000.
102
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
IA company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
Fixed asset investments
Listed
investments
Cost or valuation
At 1 January 2024
Addrtions
Disp)sals
Revaluatiorts
27,020.575
15.471.873
{17,3S8,681)
1,258,0
At 31 December 2024
,391.767
Net book value
At 31 December 2024
26,391,767
At 31 December 2023
27.020,575
Investments at market value comprise:
Tolal
funds
2024
UK
2024
Overseas
2024
Listed investments
15,866,601
751,940
9,773,226 25,639,V27
761.940
Cash held Lry investment managers
Total 24
16,618,541
9,773,226 26,391,767
The historical Gosl of the investments total £23,29),24412023." £18,105, 1691.
2024
2023
Fixed interest
2,931249
5,374,092
19,819,603 18,416,723
502,470
2,090,357
2,385,505
673,733
751,940
465,671
Equities
ProFErty
Alternatives
Cash held by investment managers
26,391,767 27 020,576
103
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
IA company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
21. Debtors
2023
Due wtthin one year
Trade debtors
Other debtors
268,310
656,677
327.855
42,671
321,707
199,467
Prepayrnents and accrued income
1.2S2.842
563,845
Creditors: Amounts falling due within one year
2024
2023
Trade creditors
Accruals and deferred incow
Other taxation and social security
Other creditors
Grants payatAe
241,057
636,962
57.047
102.348
279,617
268,262
199,406
11,769
22,096
432,308
1,317,031
933,841
Creditors: Amounts falling due after more than one year
2024
2023
Grants payatAe
145.339
146,586
104
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
IA company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
statement of funds
statement of funds - current year
Balance at
31
Gainsl December
{Lossesl
2024
Balance at 1
January
2024
Transfers
inlout
Income Expenditure
Unrestricted
funds
Designated
funds
Designated
Funds
26.700,LX)O
1S(M),LK)O)
26,2.(1)0
General funds
General Fund
431,956
2,711,283 15,316,52n
523,198
2,138,853
4,763
Total
Unrestricted
funds
27.131.966
2.711.283 15.316.627)
23.198
2.138.853 26.688.763
Endowment
funds
Endowment
Fund
90,187
1706
{2,706)
5,506
95,693
105
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
IA company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
statement of funds Icontinuedl
Balance at
31
Gainsl December
(Losses)
2024
Balance at 1
January
2024
Transfers
inlout
Income Expenditure
Restricted
funds
Kidney Machine
Children and
Young activty
breaks
34,882
34,882
15,9)3
15.C#)O
41,311
141,1961
16,018
15.IXIO
My Renal Ca
Patient
Information
Exeter arKJ
District KPA
British Gas
Energy Trust
Northern Ireland
Shared care
The Advocacy
Officer FLJnd
182,131
10S,CKIO
(221,8761
1673)
64,582
13,198
12,9821
10,216
41,414
184,917
5,792
1,600
{155.9321
15,7921
11,b))01
70.399
So,0
135,6531
14,347
Hardship,
welfare,
benefrts
1,(KlO
I1.1)0)
Wales and West
- VCMA1
250,250
(250,2501
Safe and Warm
- VCMA2
Other
691,035
78,682
{668,5101
19,5651
{22,525)
2,775
71,872
305,303
1,409,567 11,394,356)
{23,198)
297,316
Total of funds
27,S27,446
4,123,556 16,713,S891
2,144,359 27,081,772
106
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
IA company linited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
statement of funds Icontinuedl
statement of funds - prior year
Balan at
31
December
2023
Balance at
1 January
2023
Transfers
inlout
Gainsl
(Losses)
Income Expenditure
Unrestricted funds
Deslgnated funds
Designated Fund
28,000,(X)o
11,300,000)
26,700,000
General funds
General Fund
409 720 2,488,316 15,017,733) 1,3,034 1,206,619
431,956
Total Unrestricted
funds
28,409,720 2,488,316 15,017,733)
,034 1,206,619 27,131,956
EndowTnent funds
Endowment FurKi
85,177
2,102
12,1021
5,010
90,187
107
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
IA company linited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
statement of funds Icontinuedl
Balan at
31
December
2023
Balance al
1 January
2023
ExFenditur Transfers
inloul
Gainsl
(Losses)
Incorr
Restricted fund5
Kidney Machine
Children and Young
aclwity breaks
My Renal Care
Patient Information
Exeter and District
KPA
British Gas Energy
Trust
34,882
34,882
51,271
135,3681
15,903
15,000
182,131
15,000
87,200
166,916
171,9851
16,532
13,3341
13,198
148,288
9,208
3,169
178,157
2,(X)O
1106,8741
19,2081
13,1691
1178,1571
12,tK)01
41,414
Northern Ireland
Shared care
Wales and West
Scotland
Kidney Kitchen
Other
45,034
145,0341
2,775
2,775
198,648
561,784
1410,0951
145,0341
305,303
Totsl of funds
28,693,545 3,052,202 15,429.9301
1,211,629 27,527,446
108
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
statement of funds Icontinuedl
Designated funds represent amounts held as tangible fixed assets and sums that the Trustees have set
aside lo tE used for the payment of future regularly occurring grants and running costs. These sums are
not fully committed al the balance sheet dale and are held as InveslrrEnts to generate Income to facilitate
future grant payments.
Following a review of the current commitments of the charity, and lakir¥J into account the athice of our
investment fund managers, il was agreed that designated fund should reduce lo £26.2.0[
following a transfer from designated fund lo the unrestricted fund of £5.000. The transfer was made
to off-set the impact of the investment movements., the Trustees believe that this is an adequate level
required to generate sufficient InMe lo cover the regularly occurring grants and running costs, leaving
the balance on Operating Furds to te expended over the short term.
The Endowment Fund is an erdowmenl reiVed from Chris Perrol Critical Illness Trust. The income
from the Endowment Fund is also used lo provick holidays for children with kidney problems.
The Kidney Machine Fund is from a SFecific legacy bequeathed for the provision of dialysis machims.
The Children and Young Activity Breaks Fund relates to specific donations received ty the Charity lo help
fund activity breaks for children and young adults.
My Renal Care Fund relates to communication supwrt for a larger bid to NHSX ty Wessex Kidney
Centre lo promote and develop the MyRenalCare app.
The Patient Information FurKJ relates to specific donations received lo help us develop and improve our
patient information setvices, this in the form of webinars, blogs, articles in our magazine Kidney
Matters or a brochure. The transfer in the year relates to monies spent on small equiwnent.
The Exeter and District KPA Fund exists to financially supwrt kidney patients under the care of the
Exeter and Devon based hospitals.
The British Gas and Emrgy Trust IBGETI fund relates lo funding 0vided ty BGET to set-up and
SUPFM)rt our Money arKI Energy Advice service. The money and energy advisors work on a one-to-one
basis with people with kidney disease, assessing their needs arKI identifying sources of supwrt lo resolve
practi1, financial, and psychosocial challenges
The Northern Ireland Fund relates lo donations received to suptK)rt kidney patients in Northern Ireland
and the Scotland Fund relates to ck)natiorts received lo supwrt kidney patients in Scotland.
The Shared Care fLJnd relates lo SriC donation received to support our Shared Care project
The Advocacy Officer Fund relates to specific donations received to fund the Charity's Patient SuptM)rt
and Advocacy Service.
The Hardship, Welfare and Benefits Fund relates to specific donations received to SUPFK)rt individuals in
need.
The Wales and West Project relates to the expansion of our Advocacy service within Wales. The project
is focused on providing access free, irnpartial guidance and supwrt that centres around welfare with a
focus on workn.ng together to help maximise income, redu utility-relaled expenditure and sllprt overall
welltEing. The transfer In the year relates to monies stEnt on IT equipment.
The Kidney Kitchen Fund relates to Income received specificalty to fund the work arKJ development of
patient information related to kne Kidney Kitchen.
The Other fund relates to small donations received to SUPPK)rt certain areas of our charitable actwities, we
re(x)rd swh donab.ons and related expenditure through this fund.
109
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
IA company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
Analysis of net assets between funds
Analysis of net assets between funds - current period
Endowment Restricted Unrestricted
funds
funds
funds
2024
2024
2024
Total
funds
2024
Tangible fixed assets
Intangible fixed assets
Fixed asset Investments
400,834
4CQ,834
72,252
72,252
26,296,074 28.391.767
1,381,973
1,679,289
11,317,031) 11,317,031)
1145,3391 (145,3391
95,693
Current assets
Creditors due within one year
Creditors dLJe in more than one year
297,316
Total
95,693
297.316 26,688,763 27,081,772
Analysls of net assets betsveen funds - prlor perlod
Endowment
funds
2023
Restricted Unrestricted
funds
fLJrKIs
2023
2023
Total
funds
2023
Tangible fixed assets
Fixed asset Investments
404,698
404,698
26,930,389 27,020,576
877,296
1,182,599
1933,8411 1933,8411
1146,5861
1146,5861
90,187
Current assets
305,303
Creditors due within one year
Creditors due in rnore than one year
Total
90,187
305.303 27,131,956 27,527,446
110
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2W24
Reconcilialion of net nY)vement in funds to nel cash flow from operating activities
2024
2023
Net expEnditure for the [10 las KEr Statement of Fin3nGial Actwitiesl
1445.674) 11,166,099)
Adjustments for:
Depreciation and amortisalion charges
(Gainslllosses on investments
Dividends, interests and rents from investments
Lossllprofitl on the sale of fixed assets
Decre8sellinGreasel In deL*ors
Iwrease in creditors
Exchange IgainslAosses on lestrnentS
39,733
33,267
{2,144.359) 11,208,472)
1772,780) 1705,0721
1566)
1688,99n
381,943
351,439
155,938
13,1571
Net cash used in operating activities
{3,830,700) 12,542,156)
Analysis of cash and cash equivalents
2024
2023
Cash In hand
428,447
751.940
618,754
464,671
Cash held as part of Investments
Total cash and eash equivalents
1,178,387
1,083,425
Analysis of changes in net debt
At1
January
2024 Cash flows
At31
December
2024
Cash at bank and In hand
618.754
464,671
1192,30n
287.269
428,447
751,940
Cash held as part of Investments
1,083,425
94,962
1,178,387
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
IA company linited by guaranteè)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
Contingent liabilities
The charity has contingent liabilities in reference lo grants applications that have been received ty
Trustees for approval but remain conlingenl upon the applicant's completion. The total amount not
regnised in the Financial Statements amount lo £nil12023.' £310,677).
Operating lease commitments
At 31 DeCeMr 2024 the Charity had commitments lo make future minimum lease payments under non-
cancellable operating leases as follows..
2024
2023
Other
Not18ter than 1 ye8r
Later than 1 year ard not later than 5 years
2,194
7,127
2,285
1,815
9,321
4100
2024
2023
Land and Buildings
Not later than 1 ye8r
Later than 1 year aThJ not later tran 5 years
Za.(7
14,047
28,000
37,333
37,114
65.333
OFÉrating lease rentals recognised as an expense in the Statement of financial activities were £28,425
12023.. £29,922)
31. Related party transactlons
In the year, donations received from trustees lotalled £6,67212023." £3,568)
112
THE BRITISH KIDNEY PATIENT ASSOCIATION TIA KIDNEY CARE UK
(A company limited by guarantee)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
Prior year statement of financial activities
Endowment
funds
2023
Restricted Unrestricted
funds
funds
2023
2023
Total
funds
20Z3
Income and endowments from:
Fknnatiorts and legacies
Charrtable actlmlies
383.627
178.157
1,723.983
2.107.610
178.157
55.122
711,313
3,052,202
other tr&ing 8CtiMties
Invèstments
55,122
709.211
2,488.316
2.102
2.102
Total income and endowments
561.784
Expenditure on:
Raising funds
Charrtable actimlies
72
925.922
4,091.811
5,017.733
25.994
4.503,936
5,429.930
2.030
2.102
410.095
410.095
Total expenditure
Net income I (expenditure)
before net {los** I gains on
investsnents
151.689
12,529,417) (2,377.7281
1,2(.619
1.211,629
11,322,798) {1,166,0991
45.034
11,277.764) (1.166,0991
Net Ilossesl I gains on inStMentS
Net income I lexpendffcurel
Transfers LEtween funds
Nel movement in funds
5.1710
5,010
151,689
145.034)
1.655
5.010
Reconciliation of funds:
Total funds brght fopNard
Net moKemenl in funds
85.177
5.IMO
90,187
198.648
1.655
305,303
28,409.720
28.693,545
11,277.764) 11,166,099)
27,131,956
27,527,446
Total funds carried forward
113
Kidney Care UK is the UK’s leading kidney patient support charity, providing practical, financial and emotional assistance for kidney patients and their families throughout the UK. We believe that no one should face kidney disease alone.
For further details of all the support we provide to people living with kidney disease, please visit our website **www.kidneycareuk.org** or call us on 0808 801 00 00
www.kidneycareuk.org | info@kidneycareuk.org 01420 541 424 | Lines open 9am - 5pm, Monday–Friday Kidney Care UK, 3 The Windmills, St Mary’s Close, Alton, GU34 1EF
©Kidney Care UK. Kidney Care UK is the operating name of the British Kidney Patient Association. A charitable company limited by guarantee. Registered in England and Wales (1228114). A charity registered in England and Wales (270288), and Scotland (SCO48198).